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1.1. Polycystic Ovary Syndrome 
Polycystic ovary syndrome (PCOS) is a heterogeneous disorder that affects 
approximately 6-10% of women of reproductive age (Franks, 1995). Polycystic ovary 
syndrome is probably the most prevalent endocrinopathy in women and by far the most 
common cause for infertility. In fact, polycystic ovaries have been associated with 75% 
of cases of anovulation (Hull, 1987). 
 
1.2. Presentation 
The many features of this syndrome can be divided into three categories: clinical, 
endocrine and metabolic. The clinical features include menstrual abnormalities, 
hirsutism, acne, alopecia, anovulatory infertility and recurrent miscarriages. The 
endocrine features are presented with elevated androgens, luteinizing hormone, and 
oestrogen and prolactin levels. The metabolic aspects of this syndrome are insulin 
resistance, obesity, lipid abnormalities and an increased risk for impaired glucose 
tolerance and type 2 diabetes mellitus (type 2 DM). 
 
Endocrine Abnormalities  
The main endocrine features of PCOS are increased androgen production and 
disordered gonadotropin secretion. Both luteinizing hormone (LH) pulse frequency and 
amplitude are increased, whereas follicle-stimulating hormone (FSH) levels remain 
constant in the midfollicular range (Marshall et al., 1999). The frequency of 
gonadotropin-releasing hormone (GnRH) release is increased secondary to decreased 
sensitivity of the GnRH pulse generator to the negative feedback effects of estradiol and 
progesterone. This increased GnRH pulse frequency selectively increases LH release. 
The raised LH levels enhance thecal androgen production, and these androgens are 
incompletely aromatised into estrogens by the granulosa cells, because of arrested 
follicular development as a consequence of low-level cyclic FSH release. The so-called 
vicious cycle of PCOS is created, in which disordered gonadotropin secretion causes 




perpetuating disordered gonadotropin release (Dunaif, 1997). Adrenal androgen 
production is also frequently increased in PCOS (Rosenfield, 1999). This finding might 
reflect a common defect in ovarian and adrenal androgen biosynthesis because 
adrenocorticotropin hormone (ACTH) release is not increased. 
 
Metabolic Features 
Insulin resistance is a prominent feature of PCOS, independent of obesity (Dunaif, 
1992). Many but not all women with PCOS are insulin resistant. Obesity and PCOS 
have an additive deleterious effect on insulin sensitivity. The molecular mechanisms of 
this defect differ from those in other common insulin resistant conditions, such as Type 
2 Diabetes mellitus and obesity, suggesting that PCOS-related insulin resistance has an 
individual genetic aetiology (Dunaif, 1997). Studies of PCOS adipocytes suggest that 
there is a post-binding defect in insulin receptor-mediated signal transduction, and this 
observation has recently been confirmed in skeletal muscle, the major site of insulin-
mediated glucose uptake (Dunaif et al., 2001). Studies of insulin receptors isolated from 
PCOS-cultured skin fibroblasts suggested that the signalling defect results from a 
decrease in insulin receptor tyrosine kinase activity, secondary to a constitutive increase 
in receptor serine phosphorylation (Dunaif, 1997). The signalling defect produces 
selective insulin resistance, affecting metabolic but not mitogenic actions of insulin 
(Bock et al., 1999). Insulin acts through its cognate receptor, in synergy with LH, to 
stimulate theca cell steroidogenesis in PCOS (Nestler et al., 1998). Hence, it is possible 
that the selective insulin resistance of PCOS accounts for the continued actions of 
insulin on steroidogenesis, in spite of defects in insulin-mediated glucose metabolism. 
Insulin also contributes to increased adrenal androgen secretion in PCOS, in part by 
enhancing adrenal sensitivity to ACTH (Moghetti et al., 1996).  
Ek and colleagues (2002) have identified fat depot-specific abnormalities in the 
regulation of lipolysis in PCOS. Isolated subcutaneous abdominal adipocytes are 
resistant to catecholamine-induced lipolysis in women with PCOS. The opposite 
phenomenon, markedly enhanced sensitivity, is observed in  their visceral adipocytes 
(Large et al., 1998). The increase in visceral fat lipolysis could lead to an increase in 
free fatty acids (FFA) release that subsequently contributes to hepatic glucose 




one mechanism for the increased risk for glucose intolerance in PCOS (Bergman, 
1997). 
 
1.3. Polycystic Ovaries  
The classical ultrasound features of PCOS, which have been previously described 
(Adams et al., 1985) include an enlarged ovary with the presence of 10 or more cysts, 
2-8 mm in diameter, arranged either peripherally around a dense core of stroma or 
scattered throughout an increased amount of stroma. However, up to 23% of normal 
women meet the sonographic criteria for polycystic ovaries. On the other hand, many 
investigators report that ovaries from women with PCOS may be normal (Timor-Tritsch 







Figure I: Transvaginal ultrasound of the polycystic ovary 
 
1.4. Pathogenesis Of PCOS  
A series of investigations have emphasized a heterogeneous nature of PCOS with 
different combinations of features present in individual patients. The mechanisms 
involved in pathogenesis of this disorder remain up to now unclear and are 
multifactorial. There are several factors that contribute to the hyperandrogenemia and 





A primary Neuroendocrine Defect Leading To Exaggerated LH  
Pulse Frequency And Amplitude   
A persistent finding in a majority of women with PCOS is abnormal gonadotropin 
secretion, particularly, elevated levels of LH. It was hypothesized that enhanced LH 
stimulation of the ovaries results in excess androgen secretion. This hypothesis was 
supported by studies using GnRH agonists which decreased serum LH, testosterone 
and androstendione, whereas DHEA-S and other adrenal androgens were unchained 
(Steingold et al., 1987).  However, recent data from human and animal models suggests 
that the rapid GnRH pulse frequency is not a primary hypothalamic abnormality 
appreciating the effect of abnormal plasma levels of estrogen, insulin, or androgen 
(Poretsky et al., 1994; Dunaif et al., 1996; Dumesic et al., 1997). 
 
A Defect Of Androgen Synthesis That Results In Enhanced 
Ovarian Androgen Production  
PCOS theca cells show increased activity of multiple steroidogenic enzymes such as 
17-hydroxylase and 17,20-lyase, resulting in raised androgen production, both basally 
and in response to LH (Franks et al., 1999; Nelson et al., 2001). These abnormalities 
are presented in both theca cells in women with polycystic ovaries and chronic 
anovulation or women with regular ovulatory cycles and polycystic ovaries (Franks et 
al., 1999). 
Recent human and animal studies provided several mechanisms by which a primary 
defect resulting in hyperandrogenemia could cause PCOS. First, the decreased 
sensitivity of the GnRH pulse generator appears to be a consequence of raised 
circulating androgen levels, because androgen receptor blockade with flutamid 
abolishes this defect in PCOS (Eagleson et al., 2000). Second, studies on rhesus 
monkeys suggest that prenatal androgen exposure produces many features 
characteristic of the PCOS phenotype, such as increased LH secretion, ovarian 
hyperandrogenism, central obesity and defective insulin secretion (Eisner et al., 2000). 
Third, permanent alterations in LH secretion were demonstrated in women who were 
exposed to excess androgens during in utero development, such as women with 
congenital adrenal hyperplasia or with neonatal androgen-secreting neoplasm 




fourfold increased prevalence of PCO in women born since 1955 in East Germany 
following the massive application of insecticide DDT. The DDT – metabolite o, p’-DDD is 
a strong inhibitor of 3β-hydxysteroid dehydrogenase, and DDT may induce 17,20 lyase 
activity, implying a possible connection between cases of PCOS in women born after 
1955 and prenatal DDT exposure.   
 
A Unique Defect In Insulin Action And Secretion  
Peripheral insulin resistance (and associated hyperinsulinemia) plays a significant role 
for the pathogenesis of PCOS (Dunaif, 1997), and may be the primary abnormality in 
the aetiology of hormonal derangement. Insulin can directly stimulate testosterone 
synthesis in human theca cells (Nestler et al., 1998) and also contributes to increased 
adrenal secretion, in part by enhancing adrenal sensitivity to ACTH (Moghetti et al., 
1996). Insulin decreases sex hormone-binding globulin production by the liver, 
subsequently increasing free serum testosterone (Nestler et al., 1991).  
On the other hand, if insulin resistance and hyperinsulinemia have an important 
pathogenic role in PCOS, why are not all patients with hyperinsulinemia also 
hyperandrogenic, like many women with type 2 DM? Furthermore, how do ovaries 
appear to be insulin-responsive in an insulin-resistant state? 
Conn et al., (2000) showed that although 82 % of women with type 2 DM had polycystic 
ovaries in ultrasound, only 52 % had hyperandrogenism and / or menstrual 
disturbances, suggesting that hyperinsulinemia alone is not sufficient for expression of 
this syndrome.  
In another study in the group of Asian women, Rodin et al., (1998) reported that the 
effects of type 2 DM and polycystic ovaries on insulin sensitivity were independent, 
suggesting that these changes in insulin sensitivity involve different mechanisms. It is 
possible that the insulin resistance and the reproductive disturbances reflect separate 
genetic defects and that insulin resistance unmasks the syndrome in genetically 





1.5. Long-Term Disease Risks 
 The abnormal hormonal milieu characteristics of PCOS may predispose to several 
conditions, which include type 2 diabetes mellitus, hypertension, dyslipidemia, 
cardiovascular disease and some malignancies. 
 
Type 2 Diabetes Mellitus 
The association between hyperinsulinemia and hyperandrogenism was first described in 
1980 by Burghen et al. and lead to the assumption that PCOS has associated metabolic 
risks. A recent analysis of glucose tolerance among a larger group of 249 women with 
PCOS aged 14 to 44 years indicated a 31% prevalence of impaired glucose tolerance 
and a 7% prevalence of type 2 diabetes mellitus, rates significantly higher than those 
seen in among normally cycling controls (Legro et al., 1999) 
 
Cardiovascular Disease 
Women with PCOS have higher cardiovascular risk than weight-matched controls with 
normal ovarian function (Wild, 2002) due to elevated androgen levels, body fat 
distribution and insulin resistance. A number of studies have shown that women with 
PCOS exhibit an abnormal lipoprotein profile characterized by raised concentrations of 
plasma triglycerids, marginally elevated low-density lipoprotein (LDL) cholesterol, and 
reduced high-density lipoprotein (HDL) cholesterol (Dejager et al., 2001: Pirwany et al., 
2001). Furthermore, an increased hepatic lipase activity has been documented. A 
recent prospective study has linked menstrual irregularity, about 80% of which is due to 
PCOS, to increased risk of fatal coronary heart disease (Solomon et al., 2002). 
 
Cancer 
The prevalence of endometrial cancer (EM) appears to be increased in young women 
with PCOS (Niwa et al., 2000; Wild et al., 2000). Pierpont and co-workers (1998) in the 
retrospective study of 786 PCOS women and 1060 weight-matched control women in 
United Kingdom showed that women with PCOS were not at significantly increased risk 




cancer (Odds ratio 5.3). One possible mechanism is the associated high and 
unopposed level of estrogen; estrogen stimulation leads to endrometrial hyperplasia 
and subsequently to adenocarcinoma. Another theory suggests that 
hyperandrogenemia and hyperinsulinemia may increase the potential for neoplastic 
change in the endometrium through their effects on concentrations of SHBG, IGF-I and 
circulating estrogens (Meirow and Schenker, 1996). 
The results concerning an association between PCOS and ovarian cancer are 
conflicting. One group (Coulam et al., 1983) showed no risk of ovarian carcinoma 
among anovulatory women, while others (Schildkraut et al.,1996) suggested a relative 
risk of 2.5 (95% CI 1.1–5.9) in the case-control study. In the large UK study the 
standardized mortality for ovarian cancer was 0.39 (95% CI 0.01-2.17). 
 
1.6. Management of PCOS 
Women with PCOS seek medical help in order to reduce a hair growth and/or acne,  to 
restore a menstrual cyclicity and infertility. In addition, these patients are increasingly 
seeking treatment for the metabolic abnormalities such as insulin resistance and 
obesity. A “problem-oriented” approach to treatment of PCOS is the following: 
 
Oral Contraceptives  
Oral contraceptives are useful in patients with PCOS who do not desire pregnancy.  
Besides establishing regular menstrual cycle, the combined estrogen/progestin oral 
contraceptive pill inhibits endometrial proliferation and reduces ovarian androgen 
proliferation (Burkman RT, 1995). Hirsutism and acne respond well to oral contraceptive 
use. It is important to choose the appropriate oral contraceptive. Newer progestins such 
as desogestrel, as well as norgestimate and ethynodiol diacetate, have minimal 
androgenic potential and are considered to be superior to preparations, containing 








At least fifty percent or more of women with PCOS have a significant adrenal 
component to their hyperandrogenism, as evidenced by elevated concentrations of 
DHEAS. Such women generally benefit from the use of glucocorticoid preparation such 
as dexamethasone (0.5 mg/d) and prednisolone (5 mg/d). Low doses of  these drugs 
provide a good suppression of adrenal androgen secretion without significant cortisol 
suppression. 
 
Clomiphene Citrate  
The antiestrogen clomiphene citrate (CC) remains  the first-line medical therapy for 
ovulation induction in women with PCOS. The standard regimen is 50 mg/day for 5 days 
beginning on cycle day 5 following spontaneous or progestine-induced bleeding. The 
dose can be increased ( to a maximum dose of 250 mg/day) in subsequent cycles if 
serum progesterone in the luteal phase is less than 10 ng/ml. Clomiphene citrate 
induces ovulation in approximately 70% to 85% of patients, although only 33% to 45% 
conceive (Nasseri, 2001).  
An  improvement of  the outcome in clomiphene citrate cycles is possible due to adjunct 
use of hCG. The dose of 5000 or 10000 U (intramuscularly) hCG triggers ovulation and 
results in LH surge in cases in which no spontaneous LH surge is detected. 
 
Gonadotropins  
The 15% of PCOS patients who fail clomiphene therapy are treated with gonadotropins. 
The gonadotropin treatment of women with PCOS is relatively problematic because of 
high rates of multiple gestations and the occurrence of ovarian hyperstimulation 
syndrome. These problems can be avoided by use of low-dose, “step-up” regimens 
designed to result in the development of a single  dominant follicle. The treatment starts 
at the dose of 37.5 U of FSH daily on day 3 after spontaneous or progestine–induced 
menses. The dose is increased every 7 days and an ovulatory hCG trigger is given 
when the lead follicle reaches a mean diameter of 18 mm. The “step-down” protocol 
involves higher starting FSH doses, followed by dose reduction when the leading follicle 




Ovarian Drilling  
For patients who fail to respond to the use of injectable gonadotropin treatment, 
laparoscopic ovarian drilling is appropriate. The technique usually involves the  
laparoscopic cauterization of the ovarian surface (LCOS). A recent study of 1124 
patients found spontaneous ovulation in 77% and pregnancy in 49% of women (Campo, 
1998). In contrast to gonadotropins, the spontaneous abortion rate after a laparoscopic 
ovulation induction is only about 15% and multiple pregnancies are uncommon (2.5%). 
Even patients who fail to ovulate spontaneously after drilling may benefit due to 
improved response to gonadotropin treatment.  
 
Given the importance of hyperinsulinemia in the pathogenesis of PCOS, it has been 
hypothesized that  insulin-sensitizing agents may be useful in the restoration  of normal 
endocrinological and metabolic parameters.  




Metformin is thought to have primary effects on peripheral glucose uptake in response 
to insulin, with some reduction in basal hepatic glucose production (Mehnert, 2001). It 
also lowers adipose-tissue lipolysis and improves insulin sensitivity in muscle (Witters, 
2001). Its mechanism of action is not defined but recent findings suggest a unifying role 
of AMP-activated protein kinase in all the mechanisms of metformin action (Zhou et al., 
2002).The drug does not provoke hyperinsulinemia and therefore does not cause 
hypoglycaemia. It is now recommended as first-line therapy in overweight patients with 
diabetes by most leading clinical associations. It is also inexpensive. 
 
Non-Randomised Studies With Metformin  
In PCOS the first pioneer study with metformin was conducted 1994 by Velasquez and 
co-workers. Most of following trials had cohort designs and showed an improvement in 




1995; Ehrmann et al., 1997; Morin-Papunen et al., 1998; Glueck et al., 1999).  In most 
cases, small reductions were seen in body-mass index, waist/hip ratio, or both, and 
improvements in menstrual cyclicity (presumed ovulation) were also found. Only one of 
these trials (Crave et al., 1995) examined the effect of metformin on hirsutism, and there 
was no reported evidence on acne. In general, the results were encouraging, but all 
trials involved small numbers of patients, and most were of short duration and limited in 
design by not having a control or placebo group.  
Concerning a menstrual cycle, the range of benefits in uncontrolled studies is wide. The 
normal menstrual frequency was achieved in 16% (four of 24 cases) ( Crave et al., 
1995) and in more than 90% (39 of 43 cases) (Glueck et al., 1999) in women with 
PCOS. 
 
Results From Controlled Studies 
There have been seven published studies on metformin that included some form of 
randomisation (control group with or without placebo), five of them were double-blind in 
design (  Nestler et al., 1998; Moghetti et al., 2000; Morin-Papunen et al., 2000; 
Pasquali et al., 2000; Ng et al., 2001; Fleming et al., 2002; Kocak et al., 2002). The 
most consistent findings, were a decrease in body-mass index of around 4% and in 
androgen measures of around 20%, compared with placebo. The data on improvements 
in insulin concentrations and, in particular, SHBG are less convincing when considered 
together with placebo data. These observations show the potential for confounding 
effects during any prospective studies and re-emphasise the importance of control in 
study design. 
For ovulation, the most important observations were that the interval from start of 
treatment to first ovulation was significantly shorter with metformin than with placebo, 
that menstrual or ovulation cyclicity was increased with metformin, and that these 
improvements were variable and modest.  
Taken together, studies with metformin have controversial results concerning  metabolic 
changes, androgen levels, ovulatory function and pregnancy. There were many 
variations in the patients examined and the methods of assessments used. Several 




1.7. Aim Of The Trial 
Therefore, the present  randomised, double blind, placebo-controlled study was 
designed  to compare the clinical, endocrine and metabolic effects of  two treatment 
models for PCOS: 
1) Metformin and lifestyle modification, including behavioural group therapy with aspects 
in nutrition and physical activity, and individual counselling  by dietician. 
2) Placebo and lifestyle modification, including behavioural group therapy  with aspects 
in nutrition and physical activity, and individual counselling  by dietician. 
Changes  in endocrinological and metabolic parameters such as  FSH, LH, prolactin, 
estradiol, testosterone, free testosterone, DHEA-S and SHBG, total cholesterol, 
triglycerides, HDL-cholesterol, LDL-cholesterol, insulin, glucose, HbA1c, leptin and IGF-
I should be assessed before and after therapy.  Modification in insulin and glucose 
levels should be evaluated by means of AUC (area under the curve). 
The second purpose of this trial was to reveal an influence of metformin on the 
menstrual cycles and spontaneous pregnancy.  
Forty six caucasian women with PCOS aged 21 to 39 were selected in  the reproductive 
medicine department at the University Clinic Charité, Berlin, Germany. 
The patients were divided into two groups. The first group received  metformin and the 
second received a placebo during the sixteen weeks of the trial. 
All laboratory investigations: FSH, LH, prolactin, progesterone, estradiol, testosterone, 
free testosterone, DHEA-S and SHBG, total cholesterol, triglycerides, HDL-cholesterol, 
LDL-cholesterol, HbA1c, leptin and oral glucose tolerance test were performed every 8 
weeks. 
Body composition was studied by the bioelectrical impedance method at week 0, 8 and 
16. Based on Resistance ® , Reactance (Xc) and the phase angle alpha measured at 5, 
50 and 100 kHz body compartments (total body water, fat-free mass, body cell mass 
and fat mass) were calculated. 
This study was approved by the Charité ethic commission, Berlin, Germany .
SUBJECTS AND METHODS 
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2. SUBJECTS AND METHODS 
 
2.1. Patients  
Forty six  infertile women with PCOS, aged between 22 to 39 years, were recruited in 
the department of reproductive medicine at the University Clinic Charité, Berlin, 
Germany. 
Criteria of PCOS were as follows:  
1. Oligomenorrhea (less than four cycles in the last 6 months) or amenorrhoea (no 
menses in the last 4 months),  
2. Hyperandrogenemia defined by the free androgen index (FAI) greater then 5.6  
3. Presence of polycistic  ovaries according to the ultrasound criteria of Adams and co-
workers,1986. 
4. Hirsutism (Ferriman-Gallwey Score > 6) (Ferriman & Gallwey, 1961) 
5. LH/FSH ratio >2 
Women with two or more criteria were considered as having PCOS. 
All women had normal prolactin levels. The women were in good general health, 
euthyroid, and none had been taking hormonal medication or oral contraceptives during  
the three months before the initial investigation, nor during the study. None of the 
subjects had renal or liver dysfunction. The latter two criteria were determined to 
prevent risk of lactic acidosis due to metformin use.  
Impaired glucose tolerance was not the obligate criteria for PCOS, therefore oGTT was 
not included in the screening programme. 
Other exclusionary criteria comprised significant cardiovascular disease, bulimia 
nervosa, active cancer, intake of drugs affecting a body weight like diuretics, 
participation in dietary programs for weight reduction, and participation in another 
investigational study within the past 30 days.  
 
Table 1 reflects the main characteristics of the patients. 
SUBJECTS AND METHODS 
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Table 1: Clinical characteristics of PCOS women recruited in the trial  
№ Age BMI WHR 
Hirsutism 






1 24 46.4 0.86 3 yes Regular yes 2 
2 23 33.5 0,72 10 yes Oligomenorrhea yes 2 
3 24 38.6 0.69 2 yes Oligomenorrhea yes 1 
4 32 38.1 0.88 14 yes Oligomenorrhea yes 5 
5 36 31.3 0.82 8 yes Oligomenorrhea yes 1 
6 32 42.4 0.77 11 yes Regular yes 2 
7 30 40.0 0.8 9 yes Regular no 2 
8 39 39.2 0.8 12 yes Regular yes 7 
9 35 45.7 0.78 10 yes Oligomenorrhea yes 3 
10 29 42.0 0.87 9 yes Oligomenorrhea yes 7 
11 31 45.0 0.83 12 yes Regular yes 7 
12 36 46.0 0.82 11 no Regular yes 5 
13 30 43.6 0.9 9 yes Oligomenorrhea yes 3 
14 32 39.5 0.77 4 no Oligomenorrhea yes 3 
15 32 49.9 0.78 2 no Oligomenorrhea yes 10 
16 32 37.0 0.98 1 no Oligomenorrhea yes 4 
17 33 44.0 0.95 8 yes Oligomenorrhea yes 4 
18 30 38.8 0.78 4 yes Amenorrhoea yes 6 
19 28 48.0 0.85 11 no Oligomenorrhea yes 7 
SUBJECTS AND METHODS 
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№ Age BMI WHR 
Hirsutism 






20 23 37.0 0.85 10 no Oligomenorrhea yes 2 
21 37 39.3 0.89 2 no Oligomenorrhea yes 15 
22 29 41.3 0.8 12 yes Regular yes 4 
23 24 46.2 0.88 23 yes Amenorrhoea yes 4 
24 36 36.6 0.84 12 yes Oligomenorrhea yes 3 
25 28 36.9 0.78 13 yes Amenorrhoea yes 3 
26 27 33.5 0.84 10 yes Amenorrhoea yes 3 
27 31 32.7 0.89 8 yes Regular yes 4 
28 31 39.0 0.9 6 yes Oligomenorrhea yes 6 
29 28 41.0 0.84 9 yes Oligomenorrhea yes 6 
30 29 41.0 0.98 1 no Oligomenorrhea yes 6 
31 21 44.1 0.8 3 no Oligomenorrhea yes 2 
32 32 35.9 0.8 1 no Regular yes 3 
33 24 42.7 0.8 12 no Amenorrhoea yes 4 
34 28 42.1 0.9 10 yes Oligomenorrhea yes 4 
35 36 30.2 0.82 10 yes Regular yes 7 
36 28 36.3 0.89 8 yes Oligomenorrhea yes 1 
37 30 37.6 0.81 3 no Oligomenorrhea yes 1 
38 31 43.0 0.92 16 no Amenorrhoea yes 10 
39 32 44.9 0.82 9 yes Amenorrhoea yes 5 
SUBJECTS AND METHODS 
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№ Age BMI WHR 
Hirsutism 






40 27 31.0 0.88 2 yes Oligomenorrhea yes 1 
41 28 48.6 0.84 2 no Regular yes 5 
42 28 32.6 0.81 2 no Oligomenorrhea yes 1 
43 29 37.7 0.89 3 no Amenorrhoea yes 1 
44 37 36.8 0.86 9 no Oligomenorrhea yes 1 
45 26 37.4 0.9 11 yes Amenorrhoea yes 5 
46 33 45.0 0.8 9 no Amenorrhoea yes 10 
  
The mean age of patients was 29.9 ± 4.2 years. All subjects were overweight (mean 
BMI 38.1;  range 28.1 – 49.0 kg/m²) and the large majority of women  (87.5%)  had 
abdominal fat distribution defined by waist-to-hip ratio (WHR) greater than 0.8. 
11 (23.9%) patients revealed regular menstrual cyclicity, 25 (54.3%) patients had less 
than four cycles in the last 6 months and 10 (21.7%) women had chronic amenorrhoea.  
Polycistic ovaries were demonstrated by transvaginal ultrasound in all volunteers 
although  its presence is not required for diagnosis of the polycystic ovary syndrome 
(Franks, 1995). 
 
The  study protocol was approved by the ethic commission of the University Clinic 
Charité, Berlin, Germany and written informed consent was obtained from each woman 
before study. 
Metformin was helpfully granted by Berlin-Chemie, Germany. 
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2.2. Study Design 
Therapy with metformin was initiated in a randomised double-blind trial of 1500 mg 
daily. Each woman took one 500 mg  metformin tablet or an identical placebo tablet 
orally each morning, afternoon and evening for sixteen weeks. Patients were advised 
that they may have minor gastrointestinal side effects. These could be diarrhea, 
abdominal discomfort, anorexia, nausea, and rarely, a metallic taste in the mouth 
(Dandona et al., 1983). 
 
The trial included five monthly visits. Participants came to the Division of Reproductive 
Medicine between 7.00 and 10.00 a.m. after a 12-hour overnight fast. During each visit ( 
at week 0, 4, 8, 12 and 16) all the women underwent the following investigations: 
- ultrasound scanning of the ovaries,  
- recording of menstrual pattern,  
- anthropometric and blood pressure measurements, 
- recording of side-effects of metformin (if available).  
Group therapy with aspects in nutrition and physical activity was conducted monthly. 
Each woman received individual counselling by a dietician. 
 
At the first, third and fifth visits (at week 0, 8 ,16) blood for endocrine and metabolic 
measurements was obtained. Venous blood for the endocrine investigations was 
obtained before the start of the metabolic studies.  A 75-g oral glucose was 
administered, and venous blood was obtained for glucose and insulin determination, 
basally, at 60 and 120 min through the catheter. The response of glucose and insulin to 
the oGTT was analysed by calculating the AUC (area under the curve). 
Pill bottles with 90 metformin or placebo  tablets for  the next month were given at  each 
visit. 
As a monitor of general drug safety, a complete blood count with differential hepatic and 
renal characteristics was performed at baseline and after trial. 
SUBJECTS AND METHODS 
  
 21
The study was conducted from September 2002 to July 2003 in the Department for 
Reproductive Endocrinology, University Hospital Charité, Berlin. 
Limitation of the Study 
 
All blood samples were obtained without regarding the day of menstrual cycle.  
 
2.3. Methods  
Anthropometric Measurements  
BMI was calculated as weight (kg) divided by height (m) squared. Waist measurements 
were made with a soft tape midway between the lowest rib margin and the iliac crest in 
the standing position. The hip circumstance was measured over the widest part of the 
gluteal region. 
 
Blood Pressure Measurements 
Blood pressure was measured by a mercury sphygmomanometer in the sitting position, 
after a rest of at least 10 minutes. 
 
Ultrasound Examination  
Ultrasound assessments were conducted before the treatment, and at the first, fourth, 
eighth, twelfth and sixteenth week. Transvaginal ultrasonography (Logic TM 700,Probe 
7.5 MHz, GE Medical Systems, USA) was performed to evaluate the ovaries, number of 
follicles and endometrium. 
The ovaries were defined as “polycistic” when they were  enlarged (diameter over 30 
mm) with more than 8 small cysts, which are typically arranged  peripherally around an 








A determination of FSH, LH, DHEAS, SHBG, testosterone, estradiol, progesterone and 
metabolic parameters was done in the central laboratory of Charité Hospital. 
A determination of insulin, free testosterone, leptin and IGF-I levels has been 
accomplished in the laboratory of Institute for Experimental Endocrinology, Charité 
Hospital. 
 
Follicle–stimulating hormone (FSH), luteinizing hormone (LSH) and prolactin were 
measured by means of immunoassay sandwich method using direct 
chemiluminescence–technology ( Firm Chiron Diagnostics ACS, USA). Results were 
expressed in IU/ml and µg/l (prolactin). Intraassay and interassay variations varied from  
0.3% to 2.7% and 2.2% to 2.9% for FSH; 1.5% to 2.9% and 2.3% to 3.0% for LH; 2,7% 
to 3,3% and 1,4% to 4,7% for prolactin. 
 
Testosterone (T) and dehydroepiandrosterone-sulfate (DHEAS) were determined by the 
competitive immunoassay method. ADVIA Centauer Testosterone-Assay (USA) was 
used for testosterone determination. IMMULITE Analyzer (USA) was used for DHEAS 
determination. Intraassay coefficients of variation were between 2.3% and 6.2%, for T, 
6.8% and 9.5% for DHEAS. Interassay variations were between 1.4% and 4.7% for T , 
10.8% and 16.6% for DHEAS. 
 
Levels of sex hormone-binding globulin (SHBG) in serum  were determined by the 
Immunometric Assay method (IMMULITE Analyzer, USA). Results were expressed in 
nmol/L. Intraassay and interassay variations varied from 4.1% to 7.7%  and 5.5% to 
8.9%, respectively. 
 
Estradiol levels  were determined by the competitive immunoassay method using direct 
chemiluminescence–technology (Chiron Diagnostics ACS, USA). Results were 
expressed in p/ml. Intraassay and interassay variations varied from 4.5% to 8.1% and 
from 6.3% to 12.1%, respectively. 




Progesterone was determined in serum by the competitive immunoassay method using 
direct chemiluminescence–technology (Firm: ADVIA Centauer, USA). Intraassay and 
interassay variations varied from 1.9% to 5.7% and 3.7% to 12.7%, respectively. 
Thyroid hormones were determined by the competitive immunoassay method using 
direct chemiluminescence–technology (Firm Chiron Diagnostics ACS, USA). Intraassay 
and interassay coefficients of variation were between 2.41%-2.48% and 2.05%-5.31% 
for TSH; 1.81%-2.57 and 1.48%-3.48% for fT3. 
 
 IGF-I was determined by the radioimmunassay with double antibodies technique 
(Adaltis, Italy) with intraassay coefficients of variation 2.9%-5.9% and interassay 
coefficients from 4.3% to 7.1%, respectively. 
 
Serum leptin concentrations were determined by the human-Leptin–radioimmunassay 
(Mediagnost, Tübingen) with intraassay variation less than 5% and interassay variation 
less than 7.6%.  
 
Free testosterone was determined by the RIA kits by firm Diagnostic Systems 
Laboratories GmbH (Sinsheim). Intraassay variations were between 3.7% to 6.2%, 
interassay variations were between 7.3% to 9.7%. The detection limit of the assay came 
to 0.18 pg/ml. 
 
Metabolic Parameters  
 
Oral Glucose Tolerance Test 
Patients were asked to follow 300 g carbohydrate preparatory diet for 3 days before the 
test. An oral glucose tolerance test (oGGT) was performed in the morning after a 12-
hours fast.  
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For determination of glucose and insulin levels  blood samples were collected basally 
and after 60 and 120 min. A glycemic response to the OGTT was defined according to 
the criteria of the American Diabetes Association, 1997. 
 
Table 2: Criteria for the diagnosis of diabetes mellitus 





< 110 110-125 >125 
120 min post 75g 
glucose load (mg/dl) 
<140 140-200 >200 
 
 
Levels of glucose were determined by the enzymatic test by Roche Company,  
Germany. Intraassay and interassay variations were 0.8% to 1.0% and 1.7% to 1.9%, 
respectively. 
 
Insulin levels were determined by the radioimmunassay by Adaltis Italia S.p.A 
(Bologna, Italy). Intraassay variations were between 4.5% and 7.4%, interassay 
variations were between 4.2% and 8.0%. 
 
Insulin resistance 
The evaluation of insulin resistance in PCOS patients was assessed with Avignon 
insulin sensitivity index (SiM) (Avignon et al., 1999). Values of sensitivity index  less 
than one characterize insulin resistance.  Values of sensitivity index greater than one 
are supposed to be normal. 
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Cholesterol, triglycerids, creatinine, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma-glutamyltransferase (GGT) were determined by 
the enzymatic colorimetric test by Firm Roche, Germany. Results were expressed in 
mg/dl for cholesterol, triglycerids, creatinine and in U/l for ALT, AST and GGT. 
Intraassay variations laid between 0.7% to 1% for cholesterol, 0.9% to 1.5% for 
triglycerids, 0.7%-0.9% for creatinine, 0.7%-2.9% for ALT, 1.1%-2.1% for AST and 
0.3%-1.5% for GGT. 
  
HbA1c was determined by the VARIANT analysis system using high performance liquid 
technology. Intraassay variations laid between 0.94% to 1.53%, interassay variations 
laid between 1.3% to 1.8%.  
 
2.4. Free Androgen Index 
The androgen status was assessed by calculating the ratio of the total testosterone (TT) 
concentration to the concentration (or binding capacity) of SHBG. It is typically 
calculated on a molar/molar basis and rescaled by a factor ten, or one hundred or one 
thousand (Wheeler MJ., 1995). 
In this study the free androgen index was calculated as follows: (TT in nmol/L / SHBG in 
nmol/L) X 100. 
 
2.5. Questionnaires 
Patients answered questions relating to personal and family history, gynaecologic 
history like age of menarche, menstrual activity, contraception, miscarriages, 
extrauterine pregnancies, operations; weight reduction, smoking and sport activities. 
They were additionally asked to keep a nutritional protocol for seven days to estimate 
the nutritional status. Both questionnaires are attached to this paper. 
 
2.6. Dietary Composition 
Before  treatment, all patients kept a nutrition diary for four days. The nutrition status of 
each patient was analysed by Nutrition software Diät 2000. Group therapy focussing on 
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nutrition and physical activity started at the first visit and was conducted monthly. After 
treatment, patients were asked to keep a second nutrition diary and nutrition status was 
further analysed.  
Lifestyle recommendations for PCOS women included a low fat, high carbohydrates 
intake for  breakfast and high protein intake in the evening. Increased consumption of 
fibre, wholegrain bread, fruit and vegetables was also recommended. It is suggested 
that such diets aid in increased weight loss owing to the increased  satiating power of 
protein (Mikkelsen, 2002), and improve insulin sensitivity through maintenance of lean 
body mass. 
 
2.7. Metformin Treatment 
Metformin (Siofor®, Berlin-Chemie, Berlin, Germany) is a white crystalline compound 
with a molecular formula of C4H11N5▪HCl and a molecular weight of 165.63. Siofor 
tablets contain 500 mg or 850 mg of metformin hydrochloride. Each tablet contains the 
inactive ingredients povidone and magnesium stearate. The absolute bioavailability is 
approximately 50-60%. Following oral administration, 90% of the absorbed drug is 
eliminated via the renal route within the first 24 hours, with a plasma elimination half-life 
of approximately 6.2 hours (Physicians’ Desk Reference, 2000). 
Metformin inhibits hepatic glucose production, decreases intestinal absorption and 
promotes glucose uptake and utilization by peripheral tissues at the post-receptor level. 
It increases the number of insulin receptors but not insulin concentrations and therefore 
does not cause hypoglycaemia in normoglycemic patients. 
Common side effects include gastrointestinal symptoms such as nausea, vomiting, 
flatulence and diarrhea. Metformin cannot be used in patients with renal impairment 
(serum creatinine level > 1.4 mg/dL), congestive heart failure, or liver dysfunction. 
The use of metformin increases the concentrations of lactic acid through induction of 
conversion of glucose to lactate by the intestinal wall. There is no evidence to date that 
metformin therapy is associated with an increased risk of lactic acidosis or with 
increased levels of lactate compared with other antihyperglycemic treatments if the 
drugs are prescribed under study conditions, taking into account contraindications 
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(Salpeter et al., 2003). The doses of metformin used for the treatment of type 2 diabetes 
mellitus are 1-2 x 500-850 mg/d (Herold et al., 2004). 
 
2.8. Randomization  
Randomization was conducted in a double blind fashion; patients received either 
placebo or metformin according to the code provided by the pharmacy department of 
the University Clinic Charité, Berlin, Germany. The randomization code was not broken 
until the last patient completed all observations. 
 
2.9. Statistical Analysis  
The integrated glucose (area under the curve glucose [AUCg]) and insulin (AUCi) 
responses during the OGTT were determined using the trapezoidal rule. Normal 
distribution of continuous variables were tested by the Kolmogorov-Smirnov test. Both 
groups were compared by the paired Wilcoxon nonparametric sign rank test. Correlation 
analysis was performed between variables using Spearman correlation coefficient. All 
statistical evaluations were performed by the SPSS (Statistical Package for the Social 
Sciences),  Version 11.0. Differences were considered to be significant with P values 
less than 0.05, and data are reported as the mean ± SD. 
 Graphics are presented as box plots. The heavy bars represent the median values; the 
lower and upper limits of the boxes represent the interquartile range (25th and 75th 
percentiles); the I bars indicate the extreme values. 
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3. RESULTS  
 
3.1. Recruitment And Pretreatment Assessments 
A total of 46 women were recruited for the study and underwent the randomization, 
receiving metformin or placebo. Infertility was the reason for presentation for all patients 
in the both groups. Table 2 shows that the metformin and placebo groups were matched 
for age, BMI, testosterone, SHBG, fasting glucose and insulin, haemoglobin A1c, and 
circulating lipid fractions before treatment. According to Ferriman-Gallwey criteria for 
hirsutism,13 patients from placebo-treated group and 14 patients from metformin-
treated group were hirsute. All women displayed a classical picture of PCOS on vaginal 
ultrasound scan. 
 
Table 3: Characteristics of the patients randomized to receive placebo or metformin 
Parameter Placebo Metformin 
 mean ± SD mean ± SD 
Age (yr) 31.5 ± 5.3 31.7 ± 3.2 
BMI (kg/m²) 40.1 ± 5.4 40.3 ± 4.4 
Waist/hip ratio 0.84 ± 0.06 0.85 ± 0.07 
LH/FSH 1.8 ± 0.7 1.7 ± 0.8 
Total T (ng/ml) 2.7 ± 0.6 2.3 ± 0.4 
free T (pmol/L) 12.0 ± 8.5 10.7 ± 5.3 
SHBG (nmol/L) 29.8 ± 12.7 26.3 ± 10.2 
Fasting insulin (µIU/L) 18.5 ± 10.4 21.4 ± 10.1 
Fasting glucose (mg/dl) 76.7 ± 7.4 78.1 ± 14.9 
Leptin (ng/ml) 41.2 ± 13.1 38.9 ± 12.8 
Cholesterol (mg/dl) 218.9 ± 39,6 192.7 ± 40.4 
Triglycerides (mg/dl) 153.4 ± 70.3 149.8 ± 64.1 





3.2. Treatment Compliance 
There was no difference in the dropout rates between the placebo group (n=3) and 
metformin-treated group (n=3). 
All metformin-treated patients experienced mild transient diarrhoea, nausea and 
headache and one woman has dropped out of the trial due to  intolerable 
gastrointestinal side effects associated with metformin. One patient in the placebo group 
was excluded from the study because of noncompliance. Another five volunteers did not 
complete the study for personal reasons. Figure III shows the progress of these patients 




































 Figure III: Chart of patients progressing through the trial of placebo or metformin 
treatment. 
3.3. Conception During Treatment 
One patient in the metformin-treated group became pregnant in the fourteenth week of 
the treatment and gave a birth  in due time. Two spontaneous  pregnancies occurred in  
the placebo-treated group in the twelfth week of the study. One of the pregnancies in 




Pregnant patients didn’t complete the study. Their data were not included into statistical 
analysis. The statistical analysis was conducted with the data of 19 patients in the 
metformin-treated group and the data of 18 patients in the placebo-treated group who 
completed the study (see Figure III). 
 
3.4. Anthropometric Assessments 
 
Body Mass Index 
There was a reduction in the mean BMI in both groups although only in the metformin 
group body mass index and weight  decreased significantly (-5.6 kg (metformin, 
P<0.001) vs. –2.2 kg (placebo, p NS)).  The baseline BMI in the drug-treated group 
decreased from  40.6 ± 4.2 (kg/m²) to 38.9 ± 4.6kg/m² after 16 weeks. The pretreatment 
BMI in placebo-taking group was  39.5 ± 5.9 kg/m² and didn’t change after treatment 
(38.9 ± 5.6 kg/m²). 
 
Table 4: BMI measurements before and after treatment 
 Placebo    Metformin   
  n = 18   n = 19  
Parameter Pretreatment 16 wk P Pretreatment 16 wk P 
 mean ± SD mean ± SD  mean ± SD mean ± SD  

















































Waist And Hip Circumferences 
Table 5: Waist and hip measurements before and after metformin or placebo treatment 
 Placebo   Metformin   
  n=18   n=19  
Parameter Pretreatment 16 wk P Pretreatment 16 wk P 
 mean ± SD mean ± SD  mean ± SD mean ± SD  
Waist/hip 
ratio 0,84 ± 0,07 0,84 ± 0,06 NS 0,86 ± 0,06 0,86 ± 0,06 NS 
Waist (cm) 108,7 ± 9,0 107,5 ± 10,1 NS 111,4 ±  9,0 108,2 ± 10,1 0,005 
Hip (cm) 129,4 ± 12,1 127,8 ±  11,7 0,02 129,5 ± 9,5 125,4 ± 9,8 0,0001 
       
 
After 16 weeks of metformin or placebo treatment, waist circumstances decreased 
considerably in the metformin–treated group (111.4 ± 9.0 vs. 108.2 ± 10.1, p<0.005). At 
the same time, hip circumstances changed significantly in both groups although a more 
considerable decrease was demonstrated in women treated with metformin (Table 5). 
In spite of significant reduction of body mass index and both waist and  hip 
circumferences in the metformin-treated patients, no changes in the pattern of body fat 
distribution were seen. The waist-to-hip ratio remained constant in the metformin-





3.5. Endocrine Assessments  
 
Sex Hormones And SHBG  
 
Table 6: Sex hormones and SHBG blood concentrations in PCOS women before and after 
placebo or metformin treatment 
 Placebo   Metformin   
  n=18    n=19   
Parameter Pretreatment 16 wk P Pretreatment 16 wk P 
 mean ± SD mean ± SD  mean ± SD mean ± SD  
LH/FSH 1.8 ± 0.9 1.78 ± 0.9 NS 1.6 ± 0.8 1.77 ± 0.8 NS 
Prolaktin (ng/ml) 8.3 ± 2.8 10.4 ± 5.3 NS 9.9 ± 5.1 8.9 ± 4.4 NS 
total testosterone (ng/ml) 2.6 ± 0.7 2.5 ± 1.1 NS 2.1 ± 0.9 2.0 ± 0.6 NS 
free testosterone (pmol/L) 11.8 ± 8.7 8.8 ± 3.9 NS 10.3 ± 5.7 9.3 ± 5.6 NS 
SHBG (nmol/L) 30.4 ± 12.8 33.6 ± 20.6 NS 26.4 ± 10.1 34.0 ± 16.7 0.04 
DHEA-S (µmol/l) 6.0 ± 2.9 5.0 ± 2.3 0,04 6.5 ± 3.0 7.2 ± 2.9 NS 
FAI 10.0 ± 4.9 11.1 ± 8.8 NS 8.3 ± 3.5 7.4 ± 4.2 NS 
 
 
Total and Free Testosterone 
The baseline total and free testosterone concentrations were higher in PCOS women 
taking placebo compared with those taking metformin: 2.6 ± 0.7 vs. 2.1 ± 0.9 for 
testosterone (in ng/ml) and 11.8 ± 8.7 vs. 10.3 ± 5.7 for free testosterone (in pmol/L). 
There was no significant reduction in androgen levels in both groups. Figure VI shows 




































Figure VI: Box plot of free testosterone levels in women with PCOS before and after 
metformin or placebo treatment. 
 
LH/FSH Ratio 
Table 6 demonstrates that neither metformin nor placebo treatment significantly 
modified the LH/FSH ratio, FAI and prolactin parameters.  
The LH/FSH ratio remained similar after treatment in the control group: 1.8 ± 0.9 vs. 
1.78 ± 0.9  (P=0.81) and increased from 1.6 ± 0.8 to 1.77 ± 0.8 (P=0.28) in the 
metformin-taking group. The patients with random numbers 18 and 41 in the drug-
treated  group had higher LH/FSH ratios ( 4.0 for №18 ; 4.4 for  №41) and are marked 























Figure VII: Box plot of LH/FSH ratio in women with PCOS before and after metformin or 
placebo treatment. 
 
Free Androgen Index (FAI) 
The free androgen index increased from 10.0 ± 4.9 before treatment to 11.1 ± 8.8 after  
16 weeks, (P=NS)  in placebo-taking women. There were no changes of free androgen 
index in the metformin treated group (8.3 ± 3.5 to 7.4 ± 4.2, (P=NS)). 
 
Sex Hormone-Binding Globulin (SHBG) 
Placebo treatment did not substantially modify SHBG concentrations in the controls 
(30,4 ± 12,8 (nmol/L) before study and 33,6 ± 20,6 (nmol/L) after study, P=NS). SHBG 
levels significantly increased in the metformin-treated group (26,4 ± 10,1 (nmol/L) 
before study and 34,0 ± 16,7 (nmol/L) after study, P=0,04). 
Before treatment, PCOS women taking metformin seem to have slightly lower SHBG 
levels than women in the placebo-taking group. However, this difference was not 

























Figure VIII: SHBG plasma concentrations in women with PCOS before and after 






Table 7: Levels of glucose, insulin, Hb1Ac, leptin and IGF-I levels in PCOS women before 
and after placebo or metformin treatment.  
 
Glucose And Insulin 
Before treatment, fasting plasma glucose and insulin concentrations were not 
significantly different between two groups, however there was a tendency to higher 
fasting insulin levels in the metformin group.  
At baseline, 2 hours post-75-g glucose load values were increased, but not significantly 
(P=0.2), in the metformin-treated women. Five patients in the metformin-treated group 
fulfilled ADA criteria for impaired glucose tolerance vs. two patients who took placebo.  
 Placebo   Metformin   
  n=18   n=19  
Parameter Pretreatment 16 wk P Pretreatment 16 wk P 
 mean ± SD mean ± SD  mean ± SD mean ± SD  
Fasting insulin (µIU/mL) 18.3 ± 10.8 26.9 ± 13.8 0.006 21.6 ± 10.0 26.2 ± 12.1 0.04 
Fasting glucose (mg/dl) 76.8 ± 7.5 79.2 ± 8.8 NS 78.0 ± 15.3 77.11 ± 11.0 NS 
120 min glucose (mg/dl) 109.5 ± 6.8 111.6 ± 5.0 NS 124.2 ± 9.3 119.8 ± 8.4 NS 
120 min insulin (µIU/mL) 153.3 ± 26.8 112.8 ± 5.1 NS 138.9 ± 19.9 94.1 ± 14.1 0.01 
AUC,  insulin (µIU/mL·h) 261.2 ± 50.3 236.6 ± 31.1 NS 262.1 ± 34.0 211.4 ± 20.1 0.03 
AUC, glucose ( mmol/L·h) 12.8 ± 0.8 12.9 ± 0.6 NS 14.2 ± 0.7 14.8 ± 0.7 NS 
SiM index 0.86 
±
 0.8 0.8 
±




 0.53 NS 
Leptin (ng/ml) 41.4 ± 13.3 43.8 ± 17.0 NS 38.5 ± 13.1 39.6 ± 20.8 NS 




After treatment, fasting plasma and 2 hours post-75-g glucose load glucose levels did 
not change substantially in either group. However, two patients with impaired glucose 






























Figure IX: Fasting glucose levels in women with PCOS before and after metformin or 
placebo treatment. 
 
It is interesting that fasting insulin levels increased significantly both in placebo- and 
metformin-treated patients. The elevation in the placebo-treated group was from 18.3 ± 
10.8 (µIU/mL ) to 26.9 ± 13.8 (µIU/mL), P=0.006. The elevation in the metformin-treated 
group was 21.6 ± 10.0 to 26.2 ± 12.1 (µIU/mL), P=0.04. The box plots demonstrate  
fasting insulin concentrations in placebo- and metformin-treated women with PCOS 


















































Figure XI: Fasting insulin concentrations in women with PCOS before and after 
metformin treatment. 
2 hours post 75 g glucose load insulin concentrations declined significantly after 16 
weeks of metformin treatment (138.9 ± 19.9 (µIU/mL) (pretreatment) vs. 94.1 ± 14.1 
(µIU/mL) (posttreatment), P=0.01). The control group also revealed a decrease of 2  
hours post 75 g glucose load insulin levels (153.3 ± 26.8 (µIU/mL) (pretreatment) vs. 

































Figure XII: 2-hours postprandial insulin concentrations in women with PCOS before and 
after metformin or placebo treatment. 
 
Area Under The Curve (Glucose And Insulin) 
The integrated glucose response to the glucose load, AUC glucose, did not change in 
either group. AUC glucose was 12.8 ± 0.8 mmol/mL/h  before treatment and 12.9 ± 0.6 
mmol/mL/h after treatment, P=NS in the control group. In the metformin-treated group 
AUC glucose was 14.2 ± 0.7 mmol/mL/h before treatment and 14.8 ± 0.7 mmol/mL/h 
after treatment, P= NS. 
Integrated insulin response, AUC insulin, decreased in the both groups.  The decrease 
was from 262.1 ± 34.0 (µIU/mL·h) to 211.4 ± 20.1 (µIU/mL·h), P=0,03 for the drug-treated 
group.  AUC insulin changed in the placebo-taking group 261.2 ± 50.3 (µIU/mL·h) vs. 



















































Figure XIII:  Area Under The Curve insulin (AUC insulin) in metformin-treated women with 

















































Figure XIV.  Area Under The Curve insulin in placebo-treated women with PCOS before 







There were no differences in baseline leptin concentrations between PCOS women and 
controls. In spite of significant weight reduction in the metformin-treated group, leptin 
levels did not decline. Moreover, a slight increase  (38.5 ± 13.1 (pretreatment) vs. 39.6 ± 
20.8 (posttreatment) ng/ml in the metformin and 41.4 ± 13.3 (pretreatment) vs. 43.8 ± 
17.0 (posttreatment) ng/ml in the placebo-treated group ) was shown in both groups, but 
this change was not significant.  
 
IGF–I  
IGF-I levels in the metformin-treated group demonstrated a tendency to decline (160.6 ± 
84.5 (ng/ml) (pretreatment) vs. 149.1 ± 46.4 (ng/ml) (posttreatment), P= NS),  difference 
came to –11,5 ng/ml. IGF-I levels demonstrated a tendency to augment in the control 





















Figure XIV. IGF-I plasma concentrations in women with PCOS before and after metformin 







Cholesterol And Triglycerids  
 
Table 8: Serum cholesterol and triglycerids concentrations in placebo- and metformin-
treated women with PCOS before and after treatment. 
 Placebo   Metformin   
  n=18    n=19   
Parameter Pretreatment 16 wk P Pretreatment 16 wk P 
 mean ± SD mean ± SD  mean ± SD mean ± SD  
Total cholesterol (mg/dl) 216.7 ± 39.1 206.4 ± 32.7 NS 191.2 ± 40.1 196.8 ± 42.2 NS 
HDL (mg/dl) 54.3 ± 14.2 52.6 ± 10.1 NS 47.3 ± 8.4 51.0 ± 10.1 0.07 
LDL (mg/dl) 132.1± 28.6 123.4 ± 24.5 NS 114.2 ± 36.9 116.3 ± 38.5 NS 
Triglycerides (mg/dl) 152.2 ± 71.1 159.4 ± 80.1 NS 149.0 ± 65.3 148.1 ± 58.2 NS 
 
 
Table 8 shows that control women revealed higher baseline concentrations of total 
cholesterol compared to the metformin-treated group but this difference was not 
significant. Triglycerides, cholesterol and lipoprotein concentrations was in the upper 
bound of the normal range according to National Cholesterol Education Programme 
guidelines [ total cholesterol   200 mg/dl; LDL-C  130 mg/dl; HDL-C <35 mg/dl;  
 TTG >200 mg/dl] in both groups. There was no significant reduction in these 
parameters after treatment. Total cholesterol levels didn’t change in the metformin-
treated group (191.2 ± 40.1 (pretreatment)  vs. 196.8 ± 42.2 (posttreatment) mg/dl, 
PS=NS). Total cholesterol levels in the placebo-treated group were 216.7 ± 39.1 
(pretreatment)  vs. 206.4 ± 32.7 (posttreatment), P=NS. 
At the same time, circulating HDL concentrations in the metformin-treated group 
showed a trend to rise (47.3 ± 8.4 (pretreatment) vs. 51.0 ± 10.1(posttreatment)  mg/dl), 





























Figure XVI. HDL-cholesterol concentrations in women with PCOS before and after 
metformin or placebo treatment. 
 
 
3.6. Menstrual Cycle   
 
At the baseline, six (31.5 %) of the 19 women who took metformin had amenorrhea, 
eight (42.0 %) had oligomenorrhea and five (26.3%) patients had a regular menstrual 
cycle. In the placebo- treated group, four (22.2%) of the 18 women had amenorrhea, 
twelve (66.6%) women had chronic oligomenorrhea and two (11.1%) had a regular 
menstrual cycle before trial.  
After metformin treatment, in two of six patients with amenorrhea, the cycle returned to 
normal, in one woman the cycle became oligomenorrheic and three patients remained  
amenorrheic. In three of eight oligomenorrheic women, the cycle became regular. There 






Table 9: Menstrual cycle in metformin-treated women with PCOS before and after 
treatment, n=19 
 0 week 16 weeks 
Amenorrhea 6 3 
Oligomenorrhea 8 5 
Regular cycle 5 11 
 
 
 After placebo treatment, one of four amenorrheic patients became oligomenorrheic and 
three patients remained amenorrheic. In six of twelve oligomenorrheic women, the cycle  




Table 10: Menstrual cycle in placebo-treated women with PCOS before and after 
treatment, n=18 
 0 week 16 weeks 
Amenorrhea 4 3 
Oligomenorrhea 12 6 





























































Table 11: Menstrual cycle in amenorrheic patients with PCOS treated with placebo or 
metformin. 
 Metformin-treated group Placebo-treated group 
0 week 6 amenorrhea 4 amenorrhea 
 2 regular cycle  
16 weeks 1 oligomenorrhea 1 oligomenorrhea 
 3 amenorrhea 3 amenorrhea 
 
 
Metformin-treated patients were divided into two groups according to menstrual 
changes: responders (n=7) and nonresponders (n=7). Baseline characteristics of 
responders and nonresponders were compared to identify any predictors of clinical 
response to metformin treatment.  Women with regular cycle were excluded from 
analysis.  
 
Table 12: Main baseline characteristics of metformin-treated patients divided into 







BMI 41.5±4.2 38.4±3.1 NS 
total testosterone (ng/ml) 1.9±0.6 2.5±1.1 NS 
SHBG(nmol/L) 21.7±4.7 26.0±11.3 NS 
FAI 8.9±3.2 10.0±3.4 NS 
DHEAS(µmol/l) 8.6±3.1 4.4±1.3 0.005 









fasting glucose(mg/dl) 75.6±11.2 83.3±20.9 NS 
AUC insulin (µIU/mL·h) 218,9±83.1 370.8±170.2 0.05 
SIM index 0.58±0.23 0.41±0.27 NS 
 
Analysis of baseline features showed that the responders had significantly lower insulin 
levels in response to oGTT (AUC insulin) and significantly higher DHEAS levels. Fasting 
insulin levels tended to be lower in responders. There was no difference in BMI, total 
testosterone and SHBG concentrations. 
 
3.7. Subgroup Analysis 
An additional aspect of this study was an analysis of the group treated with metformin. 
The patients were divided into two groups according to the body mass index. The 
commonly accepted definition of morbid obesity is a body mass index greater than 37 
(Fleming et al., 2002). Responses were examined according to the BMI lying to either 
side of this value. The subgroup analysis was conducted to find out, first,  if an initial 
body mass could be a predictor for successful treatment with metformin. Second, if 
hazards of morbid obesity have an influence on clinical and biochemical outcomes of 
metformin treatment.  




Endocrine And Metabolic Parameters  
 





BMI < 37   
Obesity  
BMI  > 37   
  n=7    n=12   
Parameter Pretreatment 16 wk P Pretreatment 16 wk P 
 mean ± SD mean ± SD  mean ± SD mean ± SD  
BMI (kg/m²) 36.8 ± 0.8 34.9 ± 1.4 0.01 43.4 ± 3.3 41.9 ± 3.8 0.01 
LH/FSH 1.57 ± 0.7 1.77 ± 0.4 NS 1.63 ± 1.3 1.76 ± 1.0 NS 
Prolactin (ng/ml) 9.7 ± 4.3 9.2 ± 4.3 NS 10.0 ± 5.9 8.75  
±
 4.6 NS 
total testosterone (ng/ml) 2.1 ± 0.7 2.1 ± 0.6 NS 2.1 ± 1.1 2.0 ± 0.5 NS 
free testosterone (pmol/L) 9.2 ± 4.8 10.6 ± 6.7 NS 11.1 ± 6.4 8.4 ± 4.7 NS 
SHBG (nmol/L) 23.0 ± 6.8 30.4 ± 13.1 0.05 28.9 ± 11.5 36.5 ± 19.1 NS 
FAI 9.9 ± 4.2 8.0 ± 3.9 NS 7.0 ± 2.3 7.0 ± 4.5 NS 
Fasting insulin (µIU/L) 25.1 ± 10.6 24.3 ± 9.7 NS 19.1 ± 9.3 27.7 ± 13.9 0.01 
Fasting glucose (mg/dl) 73.3 ± 13.7 72.9 ± 8.7 NS 81.3 ± 16.0 80.2  
±
 11.9 NS 
AUC,  insulin (µIU/L·h) 344.0± 183.2 220.7± 102.2 0.02 202.5 ± 82.3 204.6 ± 80.3 NS 
AUC, glucose( mmol/L·h) 13.9 
±
 2.2 14.4 
±
 2.4 NS 14.5 ± 4.1 15.2 ± 3.6 NS 
SiM index 0.54 
±
 0.38 0.76 
±




 0.6 NS 
Leptin (ng/ml) 28.6±9.4 26.8±13.1 NS 45.6 ± 10.5 49.0 ± 20.7 NS 






BMI < 37   
Obesity  
BMI  > 37   
  n=7    n=12   
Parameter Pretreatment 16 wk P Pretreatment 16 wk P 
 mean ± SD mean ± SD  mean ± SD mean ± SD  
Triglycerides (mg/dl) 172.6 
±
 74.6 170.3± 70.7 NS 131.6 ± 54.7 132.0 ± 43.8 NS 
HbA1c ( %) 5.0 ± 2.06 5.5 ± 0.38 NS 6.0 ± 0.6 5.6  
±
 0.2 0.03 
 
There was no significant difference in pretreatment levels of total testosterone, SHBG 
and cholesterol among these groups. Leptin levels were significantly higher in more  
obese patients ( 45.6 ± 10.5 (women with BMI<37) vs. 28.6±9.4 (women with BMI >37)).  
However, it is interesting that women with BMI<37 have higher AUC insulin levels and  
fasting insulin levels (P<0.04) than patients with BMI>37.  
After 16 weeks of metformin treatment AUC insulin and SHBG concentrations changed 
significantly only in leaner PCOS women. SHBG concentrations increased from  23.0 ± 
6.8 to 30.4 ± 13.1 nmol/L , P=0.05. Area Under the Curve (insulin) decreased  from 
344.0± 183.2 to 220.7± 102.2 µIU/L, P=0.02. 
Fasting insulin levels increased significantly after 16 weeks of metformin treatment  in 
more obese women  with BMI>37 (19.1 ± 9.3 (pretreatment) vs. 27.7 ± 13.9 
(posttreatment) µIU/L, P=0.01). Fasting insulin levels did not change in the metformin-
treated patients with BMI<37. 
Free androgen index (FAI) showed a tendency to decrease in the leaner subgroup (9.9 










Before treatment, three of seven women with BMI<37 had amenorrhea, two had 
oligomenorrhea and two  patients had a regular menstrual cycle. In the group of patients 
with BMI>37, three of twelve women had amenorrhea, six women had chronic 
oligomenorrhea and three patients had a regular menstrual cycle. 
Table 14 demonstrates changes in menstrual history in patients with PCOS after 
metformin treatment. 
Table 14:  Menstrual cycle in women with PCOS before and after metformin treatment, 
subgroup analysis 
 
              
BMI<37 n=7           BMI>37 n=12 
 0 week 16 weeks 0 week 16 weeks 
Amenorrhea 3 1 3 2 
Oligomenorrhea 2 3 6 2 
Regular cycle 2 3 3 8 
 
 
3.8. Correlation Analysis 
 
The correlation analysis was undertaken to reveal  a relationship between several 










Leptin level correlated strongly with Body Mass Index in women with PCOS (r=0.53, 























AUC insulin significantly correlated with free androgen index (r=0.38; P<0.01). 
 























A significant inverse correlation between fasting insulin and HDL cholesterol levels 


























Figure XXI. Correlation between HDL total cholesterol and fasting insulin 
in women with PCOS, n=46                                    
 
A significant positive correlation between 2-hours insulin and total cholesterol (r=0.5; 
P<0.002) was shown. 
 

















Figure XXII. Correlation between total cholesterol and 2 hour insulin in  





3.9. Menstrual Cycle 
 
There was a strong correlation between menstrual disfunction  and insulin resistance in 
the whole group. As one can see in the table 13, eight of ten (80%) patients with 
amenorrhea fulfilled criteria for insulin resistance (Insulin sensitivity index (SiM)<1). 
Eighteen of twenty (80%) oligomenorrheic women had insulin resistance as well. There 
were three of seven (42.8%) patients with regular cycle who fulfilled criteria for insulin 
resistance. 
Table 15:  Menstrual disfunction and insulin resistance.  





  mean±SD mean±SD mean±SD 
Insulin Sensitivity Index (SiM) 0.54±0.31 0.57±0.3 1.4±1.1 
  8 of 10 (80%) 18 of 20 (80%) 3 of 7 (42.8%) 
 
IGF-I 
After 16 weeks of metformin treatment changes in IGF-I level correlated with changes in 
AUC insulin (r=0.56, P<0.01). 
 Metformin-treated group
























Figure XXIII. Correlation between changes  in IGF-I levels and AUC insulin in the    
metformin-treated group, n=19   
Changes in IGF-I level showed a tendency to correlate with changes in HDL-cholesterol 
concentrations (r=-0.59; P<0.008) in the metformin-treated group. 
 
 Metformin- treated group





















Figure XXIV. Correlation between changes in IGF-I and HDL cholesterol levels in the 







In this study on women with PCOS, treatment with metformin resulted in a significant 
decrease in body mass index, improvement of insulin action with a parallel increase of 
SHBG concentrations. This study contributed to a few randomized double blind placebo 
controlled trials and assessed metformin effects on metabolic and endocrine profiles in 
polycystic ovary syndrome.  
 
 
4.1. Body Weight And Body Mass Index 
 
In the metformin-treated group, mean body mass index averaged from 40.6 before the 
trial to 38.9 after trial. The absolute difference in these two values was 1.7, which came 
to a 4.2% reduction in the mean BMI after metformin therapy. Decrease of BMI in the 
placebo-taking group was not significant. These findings are consistent with results of 
almost all observational studies, where a decrease in the BMI ranged from 1% to 
approximately 4.3%.  
Velasquez et al. (1994); Glueck et al. (1999); Kolodziejczyk et al. (2000) additionally 
found an improvement in menstrual cyclicity during metformin therapy. The metformin-
induced weight loss was supposed to be the real cause of improvement rather than 
direct actions of metformin. It is also well documented in the study by Kiddy and co-
workers (1992) that more than 5% decrease in body weight can mitigate reproductive 
abnormalities. However, the following four double-blind placebo control studies of 
Moghetti et al. (2000); Morin-Papunen et al. (1998); Kocak et al. (2002) and Fleming et 
al. (2002) did not find a significant decrease in BMI despite the amelioration in 
hyperinsulinemia and hyperandrogenism. Furthermore, in the study by Moghetti et al., 
the metformin group had a significantly lower body mass index than the placebo group, 





To answer the question if weight loss with metformin is better than weight loss alone, 
three trials comparing effects of low calorie diet and metformin therapy were conducted. 
In a randomized control trial (RCT) including 18 obese women with PCOS, all subjects 
were given a low calorie diet for 1 month before and during 6 months of the study 
(Pasquali et al., 2000). Ten were treated with metformin and 8 with placebo. In a further 
trial by Casimiri and colleagues (1997), 24 patients were given a low calorie diet with 
placebo or metformin for 26 weeks. In both studies, compared with placebo, metformin 
improved insulin sensitivity, lowered testosterone levels and improved ovulatory and 
menstrual functions. One placebo-controlled 16-weeks study was not able to 
demonstrate any additional effect of metformin over-dieting (Crave et al., 1995). The 
subjects were all hirsute and very obese (mean BMI 35,2 kg/m²) and only 15 of the 24 
women had polycystic ovaries on ultrasound. They may represent a particularly difficult 
group to treat successfully.  
 
Lean PCOS subjects can experience similar hormonal and metabolic improvements 
during metformin treatment compared to obese women. Most of the beneficial changes 
were observed after 3 months of the treatment and at a dosage of 1 g/d. It was 
hypothesized  that lower doses of metformin than those used in obese PCOS women 
could be sufficient in lean women (Ibanez et al. 2001; Morin-Papunen et al., 2003). 
 
However, while metformin mainly affects central obesity and lipid metabolism, with 
minimal effects on hepatic clearance, its action seems to be focused mainly on hepatic 
clearance of insulin and steroid secretion in non-obese patients. This result suggests a 
particular characteristic of PCOS in non-obese women or the fact that obesity acts as a 
confounding factor of this disease (Morales et al.,1996). 
 
In this study, significant weight loss was achieved only in the metformin-treated group, 
although all patients were advised to follow dietary restriction and to do regular physical 
exercises. Therefore, it was concluded, first, that metformin could contribute to weight 




of RCTs (where metformin was administrated without dietary restriction) if metformin is 
combined with a hypocaloric diet or/and regular physical activity.  
4.2. Body Fat Distribution and Waist-Hip Ratio 
 
 
The majority of PCOS women are obese or overweight, however, obesity is not the 
obligatory feature of this syndrome. Of special importance is the amount of body fat and 
especially the sex specific kind of fat distribution, which can be indicators of the 
hormonal and reproductive status of woman. Up to now few studies analysed fat 
distribution patterns in obese and lean PCOS patients (Bringer et al.,1993; Douchi et al., 
1997; Lefebvre et al., 1997; Kirchengast et al., 2001). The authors were able to  tended 
to an android (abdominal) fat pattern in PCOS women in comparison with weight-
matched control women.  
 
The present study found a significant decrease in waist and hip circumferences in 
PCOS patients after metformin treatment. These data are in agreement with the results 
of all other studies that examined metformin effects on obese PCOS women. Pasquali 
and co-workers measured, by CT scan, additional anthropometric parameters, such as 
total adipose tissue (TAT), visceral adipose tissue (VAT) and subcutaneous adipose 
tissue (SAT). Whereas obese PCOS subjects lost significantly more visceral fat in the 
abdomen without any significant changes of SAT after metformin, the opposite was 
observed in the control obese group. These findings, therefore, suggested  particular 
effect of metformin on visceral adipose tissue in PCOS.  
In this study, metformin-treated women lost significantly more abdominal fat (waist 
circumference) compared to controls. A loss of hip circumference was obvious in both 
groups, however, a waist-to-hip ratio remains constant after 16 weeks of metformin or 
placebo treatment.  
 
Available data seem to support the concept that PCOS and abdominal obesity have a 
negative impact on insulin sensitivity (Dunaif A., 1997). The study by Pasquali and co-




different patterns of body fat distribution showed that hyperinsulinemia was more 
correlated with abdominal fat distribution, regardless of PCOS. In addition, Holte et al. 
(1995) indicated that hyperinsulinemia and insulin resistance might be significantly 
reversible through reduction or normalisation of abdominal fat depots. Therefore, it is 
hypothesized that abdominal (visceral) fatness may have a  dominant role in 
determining these abnormalities in most women with PCOS, regardless of other factors, 
including genetic predisposition (Dunaif A., 1997). 
 
4.3. Reproductive Hormones  
 
Sex Steroids And SHBG 
 
The absence of change in total testosterone concentrations was accompanied by a rise 
in SHBG levels in this study. This has also been reported by Velasquez and co-workers. 
The increase in SHBG was not unexpected, due to the experimental data supporting the 
role of insulin in the regulation of hepatic SHBG production (Nestler et al., 1991). 
Patients demonstrated a significant increase in SHBG concentrations parallel to the 
decrease in total insulin response.  
 
A weak inverse correlation between SHBG, fasting insulin levels and insulin levels in 
response to oGTT was revealed. This correlation was previously shown in both healthy 
subjects and hyperinsulinemic disease situations such as PCOS and type 2 diabetes 
(Sharp et al., 1991; Katsuki et al., 1996 and Jayagopal et al., 2003). The strong 
association prompted suggestions that a low level of SHBG could be used as a marker 
to identify individuals with insulin resistance.  
 
In this study it was postulated that metformin would alter ovarian steroid production in 
women with PCOS. This hypothesis is based on finding that metformin treatment 
ameliorates the hyperinsulinemia and hyperandrogenemia (Velasquez et al., 1997; 




17,20-lyase activities of the ovarian steroid-forming P450c17 alpha (Ehrmann et al., 
1995). These enzymes are characteristically abnormally regulated in women with 
ovarian androgen excess in PCOS. 
 
Contrary to postulates and results reported by most of other studies, except two 
(Ehrmann et al., 1997; Fleming et al., 2002), no significant changes in serum total and 
free testosterone levels after treatment with metformin were found.  
 
On the other hand, a recent study by Maciel et al. (2004), that compared effects of 
metformin in obese and non-obese patients with PCOS, presented similar results: 
whereas lean women showed significant decrease in serum total testosterone levels 
after 6 months’ metformin therapy (1,5 g daily), obese patients demonstrated only an 
improvement in SHBG levels but not in serum total testosterone levels.  
 
Hence, it could be suggested that the major effect of metformin in obese women on 
androgen secretion is mediated by changes in hyperinsulinemia and subsequently in 




After 16 weeks of treatment, DHEAS concentrations significantly decreased in the 
placebo-treated group. DHEAS levels in the metformin-treated women showed a 
tendency to rise. 
 
Nestler et al. (1994) demonstrated that metformin administration increased DHEAS 
levels by 80 % in non-obese women. Kolodziejczyk et al., (1999), Kazerooni et al., 
(2003) have reported the same results in obese women with normal DHEAS levels.  
However, when effects of metformin were analysed separately in subgroups, a 




DHEAS concentrations (>10.3 µmol/l). The authors supposed that hyperinsulinemia 
inhibits adrenal 17,20-lyase and thus decreases DHEAS production. 
Nevertheless, the interactions between DHEAS and insulin are still poorly understood. A 
negative correlation between these hormones has been reported (Schriock et al., 1988); 
furthermore, acute infusion of insulin or an increase of insulin induced by the oral 
glucose tolerance test led to a decrease in DHEAS levels in healthy subjects (Diamond 
et al., 1991). However, a decline in DHEAS was not observed after insulin infusion in 
women with hyperandrogenism and hyperinsulinemia (Falcone et al., 1990).  
 
In the present study, the decrease of insulin levels was not accompanied by significant 
change in DHEAS in the metformin-treated group. It was not possible to conduct a 
subgroup analysis according to the baseline DHEAS levels since there were only four 
patients with elevated DHEAS concentrations in the entire treated group. Based on 
results of previous studies, one can speculate that the adrenal response to declining 
levels of insulin may be dependent on the baseline adrenal function. 
  
Adrenal function  can be modulated by the IGF system. Receptors and binding proteins 
for IGF have been identified in adrenocortical tissues; furthermore, both IGF-I and IGF-II 
have been shown to stimulate DHEAS production through type I IGF receptors (Fottner 
et al., 1998). Thus, it was expected that metformin treatment would result in a decline in 
DHEAS along with IGF-I. However, DHEAS declined only in the placebo-taking group 
and this decrease was not associated with any changes in IGF-I levels. This finding 
underscores the complexity of interactions between adrenal steroidogenesis and the 





The present study was not able to demonstrate any changes in FSH and LH 
concentrations after metformin therapy. These results are consistent with most of 




emphasize that the blood samples were obtained without regard to the menstrual cycle. 
The  LH/FSH ratio was used  to asses the hypothalamic function in our patients. 
 
The prevalence of increased serum LH in PCOS ranges from 30% to 90% (Rebar et al., 
1976; Franks, 1989). The reasons for these variations are unclear but probably include 
the heterogeneity of PCOS, a variable occurrence of associated obesity, different blood 
sampling frequencies, and the specificity of the gonadotropin assays.  
 
Studies of rat pituitary cells in vitro suggested that hyperinsulinemia may potentiate both 
LH and FSH release to GnRH.  However, these results have not been confirmed by all 
in vivo studies and only in two studies was a decrease in plasma insulin by the 
administration of metformin or troglitazone associated with a reduction in mean LH 
concentrations (Nestler et al., 1996; Dunaif, 1996). Additionally, obese women with 
PCOS have higher levels of plasma insulin, but the mean LH was unchanged or lower 
compared with the level in lean women (Morales et al., 1996).  
Thus, the effects of insulin and consequently insulin sensitizers on gonadotropin 
secretion remain unclear and further research needs to be done.  
 
4.4. Insulin And Glucose Metabolism  
 
According to Dunaif et al. (1987), up to 20% of obese PCOS women have impaired 
glucose tolerance or frank type 2 DM. This is in agreement with the results of our study, 
where seven (18%) women had increased 2-hours glucose concentrations in response 
to oGTT and one patient showed increased fasting glucose levels at the beginning of 
the study.  
 
We observed no changes in glucose levels (both fasting and after glucose load) and 
glycosylated haemoglobin A1c concentrations in  the metformin- or in the placebo- 
treated group. These data are consistent with results obtained in most studies in PCOS 





Before the study, we found a highly significant correlation between AUC insulin and 
androgenicity measured by the free androgen index (FAI). Several previous studies 
have also demonstrated this positive correlation (Burghen et al., 1980; Lobo et al., 
1983). Furthermore, the severity of hyperinsulinemia correlates with the degree of 
clinical expression of PCOS syndrome (Robinson et al., 1993). 
 
Whether hyperandrogenism results from hyperinsulinemia, or vice versa, has been 
debated since this correlation was demonstrated. The experiments in which 
hyperandrogenemia was diminished by bilateral oophorectomy (Nagamani et al., 1986) 
or the administration of GnRH-agonist (Dunaif et al., 1990) did not demonstrate 
changes in the hyperinsulinemic stage in women with PCOS. Diamanti-Kandarakis et 
al., (1995) reported that antiandrogen therapy did not alter insulin sensitivity in PCOS. 
Studies in which insulin levels have been lowered by agents that either decrease insulin 
secretion such as diazoxide (Nestler et al., 1989) or somatostatin (Prelevic et al., 1990); 
or improve insulin sensitivity such as metformin (Velasquez et al., 1994) or troglitazone 
(Dunaif et al., 1996) indicated a decrease of androgen production in PCOS. In 
summary, these findings demonstrate that disordered insulin action precedes the 
increase in androgens. 
 
Most of studies demonstrated reduced insulin sensitivity in both obese and non-obese 
women with PCOS syndrome (Dunaif et al., 1992; Morales et al., 1996).  
The effects of metformin therapy on insulin sensitivity in PCOS remain controversial.  
Some investigators, assessing insulin sensitivity by way of the intravenous insulin 
tolerance test  (Unluhizarci et al., 1999) or the euglycemic clamp technique (Diamanti-
Kandarakis et al., 1998; Moghetti et al., 2000), have shown significant improvement of 
insulin sensitivity after metformin use. Other authors have failed to confirm this (Acbay 
et al., 1996; Ehramann et al., 1997; Crave et al., 1995).  
 
The possible reason for this discrepancy is that there is no consensus for the most 




technique is still regarded as the gold standard diagnostic test. Its routine use in the 
clinical setting is not practical for large randomized studies and was used only in three 
trials (see above). Other investigators used indices such as fasting glucose-to-insulin 
ratio, homeostasis assessment model (HOMA) and quantative insulin sensitivity check 
index (QUICKI). The Avignon sensitivity index (SiM) was used in this study to assess 
insulin sensitivity. It was shown by Chiampelli and co-workers (2005) that SiM has the 
best correlation with the hyperinsulinemic euglycemic clamp technique. 
We did not directly measure insulin sensitivity by mean of clamp technique, however, 
we calculated the Avignon sensitivity index (SiM) and the measured substitute markers 
of insulin sensitivity, such as fasting serum insulin and serum insulin excursion after oral 
glucose ingestion.  
There was a significant decrease in integrated insulin response to oGTT (AUC insulin) 
in the metformin group compared with controls. However, fasting insulin levels 
increased after both metformin and placebo treatment despite the amelioration of insulin 
action in response to oral glucose. These findings are partly in agreement with reports 
by Velasquez et al., (1997); Pasquali et al., (2000); Gambineri et al., (2004) who 
demonstrated considerable increase of insulin concentrations both fasting and after 
glucose load.  
 
We analysed baseline predictors of clinical response to metformin according to efficacy 
of treatment on menstrual disturbances. Responders differed from nonresponders in 
several characteristics.  Responders had significantly lower insulin levels in response to 
oGTT (AUC insulin) and significantly higher DHEAS levels. Fasting insulin levels 
showed a tendency to be lower in responders. The degree of insulin resistance (SIM 
index) tended to be more pronounced in nonresponders. It is important to notice that the 
majority of patients in both responder and nonresponder groups were insulin-resistant 
but the degree of insulin resistance was more severe in nonresponders. These data 
appear to suggest that metformin treatment may be effective in hyperinsulinemic and 





An unexpected finding of this study was the increase of fasting insulin levels in PCOS 
women after metformin treatment. Series of studies by Acbay et al., (1996); Ehrmann et 
al., (1997); Vandermolen et al., (2001); Fleming et al., (2002) revealed no changes in 
fasting insulin levels after metformin treatment. It is important to note that patients in 
these studies were manifestly obese (mean BMI ~ 37.6 –39.1) like women in the 
present study (mean BMI = 39.3).  
 
Ehrmann and co-workers supposed that the ability of metformin to alter insulin secretion 
in obesity of this magnitude appears to be limited. This hypothesis could explain the 
results of subgroup analysis which revealed a significant decrease in insulin 
concentrations in response to oGTT in patients with BMI<37 after 16 weeks of 
metformin treatment. There were no changes in insulin concentrations in response to 
oGTT in patients with morbid obesity. At the same time, no changes in insulin fasting 
levels in women with BMI<37 were observed. Patients with BMI>37 demonstrated a 
significant increase of fasting insulin levels after 16 weeks of treatment with metformin.  
 
In the present study,  less obese women had higher fasting insulin concentrations and 
in response to oGTT insulin concentrations at baseline compared to more obese 
patients. This suggests that metformin treatment can be more efficient in 
hyperinsulinemic PCOS patients irrespective of their obesity. 
 
A recent study of Maciel et al., (2004) comparing effects of metformin in obese and 
nonobese women with PCOS in a placebo-controlled trial demonstrated for the first time 
that non-obese women with PCOS respond better than obese women to metformin 
treatment at a dosage of 1500 mg/day for 6 months.  
 
Thus, an alternative explanation for these findings and those of the present study 
include the possibilities that metformin was administrated in a dose or duration that was 





4.5. Insulin Like Growth Factor-I  
 
The IGF-I levels remained unchanged during the study. Nevertheless, IGF-I 
concentrations in the metformin-treated group demonstrated a tendency to decline. This 
tendency was much stronger in less obese patients who demonstrated a 20% decrease 
(P not significant), whereas metformin treatment did not modify IGF-I levels in more 
obese women. 
 
Similar results are reported by Kowalska et al. (2001) and De Leo et al. (2000). In 
addition, De Leo and colleagues observed a significant increase in IGF-I binding protein 
concentrations in women with PCOS after 30-32 days of metformin treatment. They also 
calculated the IGF-I/IGF-I binding protein ratio, which was significantly reduced too. 
Significant changes were  also observed in IGF-I and IGF-I binding protein 
concentrations after therapy with another insulin-sensitizing drug, rosiglitazone (Belli et 
al., 2004). 
 
IGF-I may contribute to ovarian hyperandrogenemia in PCOS. The in vitro-study by 
Nahum et al. (1995) documented that IGF-I stimulates androgen output by increasing 
DNA synthesis and expression of LH-receptors  in theca cells. IGF-I has been shown to 
cause estrogen production by granulosa cells (Erikson et al., 1990) and to act 
synergistically with FSH and LH controlling aromatase levels in granulosa cells.  
 
In PCOS, plasma IGF-I levels are within the normal range, whereas serum IGF-I binding 
protein (IGFBP-I) levels are reported to be significantly lower than in normal women. 
Insulin has been shown to reduce IGFBP-I concentrations, inhibiting its production in 
the liver. This leads to an increased bioavailability of IGF-I to the ovaries and 
subsequently to stimulation of androgen production.  
 
Insulin in high concentrations can also mimic IGF-I effects by acting via IGF-I receptor 




responsible for insulin-mediated hyperandrogenism. However, insulin has been shown 
to bind the IGF-I receptor with an affinity of 50-500 times lower than that of IGF-I. 
Moreover, Willis & Franks, 1995, using anti-insulin receptor and antitype-I IGF receptor 
antibodies, not only demonstrated that insulin effects on human granulosa cell 
steroidogenesis in vitro must be mediated via its own receptor, but also excluded both 
the insulin/type-I IGF hybrid receptor and the type-I IGF receptor as possible insulin 
action-mediated receptors. 
 
The subgroup analysis revealed a strong positive correlation between changes in IGF-I 
concentrations and AUC insulin after metformin treatment in less obese women. Hence, 
based on the report of De Leo, Belli and colleagues, we could imagine that the lowering 
of insulin levels with metformin would be responsible for the increase in IGFBP-1 




Before treatment, a positive correlation between BMI and serum leptin levels was 
observed, as previously reported (Krotkiewski et al., 2003). The subgroup analysis 
revealed significant higher leptin concentrations in women with BMI>37 than in women 
with BMI<37. Consequently, circulating leptin appears to be a  predictor for body mass 
and percentage of body fat. 
 
In spite of significant weight reduction after metformin treatment, leptin levels did not 
decline. We could not find any explanation for this finding. It was hypothsized that the 
metformin effect on the leptin secretion may occur during the prolonged therapy. 
Another hypothesis is that changes in body mass are not accompanied by changes of 
leptin concentrations immediately and need some time to adapt. 
 
Leptin is the hormone product of the obesity (ob) gene and is synthesized exclusively in 




resulting in the suppression on food intake and increase of energy consumption. Leptin 
deficiency and high leptin levels are both associated with infertility (Barash et al., 1996). 
 
A potential contribution of leptin to the pathogenesis of PCOS was suggested in a study 
by Brzechffa and colleagues (1996) in which a subgroup of women with PCOS 
appeared to have higher leptin levels than controls. However, the majority of research 
supported the view that serum leptin concentrations in women with PCOS are not 
significantly different from a control group with a similar BMI  (Chapman et al., 1997; 
Laughlin et al., 1997; Maliqueo et al., 1999).   
Several studies suggest that leptin modulates hypothalamic–pituitary–gonadal axis 
functions. Leptin may stimulate the release of gonadotropin releasing hormone (GnRH) 
from the hypothalamus and of gonadotropins from the pituitary. A synchronicity of LH 
and leptin pulses was demonstrated in the follicular phase of the menstrual cycle of 
healthy women (Licinio et al., 1998) and in patients with polycystic ovarian syndrome 
(Sir-Petermann et al., 1999), suggesting that leptin may regulate the episodic secretion  
of LH. 
On the basis of our results, we could not demonstrate any correlation between leptin 
and LH levels. However, we measured a one-off secretion and not pulsatile hormone 
concentrations, as described.  
Studies of insulin regulation of leptin in human yielded conflicting results. This 
relationship was investigated in a detailed study by Laughlin et al. (1997). They found 
that independently of body mass and percentage body fat, only 24-hour mean insulin 
concentrations contributed significantly to leptin levels. Despite this relationship and the 
2-fold higher mean insulin concentrations in patients with PCOS compared with 
controls, serum leptin was not increased. The authors explained their results by the 
presence of a PCOS-specific form of insulin resistance in adipocytes, which impairs the 
stimulatory effect of insulin on leptin secretion. Additionally, it is considered that leptin 
secretion in women with PCOS is less than expected because of insulin resistance and 






This hypothesis could explain our findings where the improvement of hyperinsulinemia 
did not alter leptin levels despite the significant weight reduction. The present results 
are in agreement with the studies by Mantzoros et al, (1997) and Belli et al., (2003), 
who also found no changes in leptin concentrations after treatment with 




Triglycerides, cholesterol and lipoprotein concentrations approached  the upper limit of 
the normal range and did not significantly change after treatment. Nevertheless, HDL 
cholesterol levels in the metformin-treated group showed a tendency to rise, but P=0.07 
did not achieve a significant value. These findings are in line with the results obtained 
by Moghetti et al., (2000) who found modest improvement in HDL- cholesterol levels 
after six months metformin treatment. In most studies on women with PCOS, metformin 
and other insulin-sensitizing agent, like troglitazone produce no improvements in 
dyslipidemia in women with PCOS (Velasquez et al., 1997; Morin-Papunen et al., 1998; 
Legro et al., 2003). Interesting results have been presented in the study of Gambineri 
and colleagues (2004), who investigated the effects of long-term metformin and 
flutamide treatment, given alone and in combination.  
Whereas flutamide administration showed a significant reduction of total and LDL 
cholesterol, the combined metformin + flutamide therapy tended additionally to increase 
HDL levels. The effects on total and LDL cholesterol appear to depend on the 
antiandrogenic effects of flutamide. Androgens are known to be directly involved in the 
regulation of cholesterol and lipoprotein metabolism (Anderson et al., 2002). The 
interaction between metformin and flutamide appear to confirm the role of insulin and 
androgens on HDL metabolism (Von Eckardsein, 1998). 
 
Multiple studies have also reported that insulin resistance has been associated with 
decreased HDL-cholesterol and elevated triglyceride levels in PCOS women (Robinson 
et al., 1996; Rajkhowa et al., 1997; Mather et al., 2000). This finding is in agreement 




correlation between fasting insulin and HDL cholesterol, and a significant positive 
correlation between 2-hour insulin and total cholesterol. 
 
To summarize, HDL cholesterol concentrations demonstrated a noticeable trend to rise, 
and we can suppose that metformin treatment may have an impact on lipids as 
cardiovascular risk factors.  
4.8. Menstrual Abnormalities  
 
 
After metformin treatment, in two of six patients with severe amenorrhea, the cycle 
returned to normal, one woman became oligomenorrheic and three patients remained  
amenorrheic. After placebo treatment, one of four amenorrheic patients became 
oligomenorrheic and three patients remained amenorrheic. There were no patients in 
the placebo treated group who returned to regular cycle. These results appear to 
suggest that metformin administration was associated with improvement of menstrual 
function in PCOS women with severe menstrual disorders.  
 
Several studies have documented the restoration of regular menstrual cycles and 
supported that this effect is not limited to a single ethnic group or geographic area 
(Nestler et al., 1996; Pirwany et al., 1999; Glueck et al., 2001; Kazerooni et al., 2003). 
Nonetheless, most of these studies were small and uncontrolled. There are only two 
controlled and randomized trials demonstrating a significant improvement in regular 
menstrual cycles with metformin (Moghetti et al., 2000; Fleming et al., 2002). 
 
In the present study, 50% of the women given metformin  experienced no improvement 
of their menstrual cycle. The reasons for the differences in clinical response to 





Kolodziejczyk et al. (2000) found that the improvement in the length of the menstrual 
cycle was significantly greater in women with high DHEAS levels (>400 µg/dL or  >10,3 
µmol/l) than in those with normal DHEAS. 
 
Moghetti et al. (2000), based on multiple regression analysis, predicted clinical 
improvement for PCOS patients treated with metformin. These predictors were higher 
plasma insulin levels, less severe menstrual abnormalities  and lower serum 
androstendione levels. These data strengthen the hypothesis that metformin may be 
effective only in the insulin-resistant subjects. 
 
By contrast, subgroup analysis in the study by Fleming and co-workers (2002) revealed 
that body mass index and insulin resistance did not predict the ability to establish 
normal ovarian function and menstrual cycle. High SHBG concentrations and lower free 
index predicted the ability to establish normal ovarian function and menstrual cycle. 
 
Pirwany et al.  (1999) focused on the effect of metformin alone on menstrual cyclicity 
and ovulation rates. They also divided women into subgroups to see if various baseline 
parameters predicted a response to metformin. For example, patients with elevated 
testosterone levels had significant improvements in ovulation rates: 14. 8% to 38.9% (P 
= 0.005). Similarly, the subgroup of patients with fasting hyperinsulinemia (FI > 14 
mIU/ml) at baseline had a significant increase in ovulation rate from 12.5% to 39.4% (P 
= 0.012). However, those with normal baseline insulin concentrations did not show an 
improvement.  
 
 We would draw a parallel between our own finding and those obtained by Douchi et al., 
(2002). The author and his colleagues examined eighty-three obese women (mean BMI 
= 31.9) who were divided into two groups according to their menstrual status: one with 
menstrual disorders and the other group with regular menstruation. They compared 
anthropometric characteristics between the two groups and found that women with 




postulated that upper body obesity and not a degree of obesity, are associated with 
menstrual disorders.  
 
We provided a subgroup analysis in order to test if body weight is an important factor for 
successful treatment with metformin. There was no difference apparent between 
women with BMI<37 and morbid obese patients in the menstrual response to treatment. 
This finding suggests that body weight possibly is not a predictive factor for menstrual 
response to metformin treatment.  
The data of the present study are in agreement with results obtained by Fleming and 
colleagues (2005). The authors showed no difference between obese and morbid obese 
groups in the proportions attaining a normal menstrual rhythm.  
In the present study, the subgroups contained small numbers of subjects (seven and 
twelve patients each). Large numbers of patients will be required to show convincing 
differences in many parameters.  
  
Therefore, we concluded that until now there are not enough data to limit metformin 
treatment to a specific subgroup of women with PCOS. One of the factors to be 
determined is the relationship between dose and body mass index. 
 
4.9. Metformin and Pregnancy Rates 
 
There were three conceptions in three patients during the study, and one miscarriage in 
the first trimester. The distribution of pregnancies was: metformin, 1 of 23 patients; and 
placebo, 2 of 23 patients. This finding is a surprising observation, taking into account 
that menstrual cyclicity improved in the metformin-treated group. However, there were 
some limitations that could explain the results of the study. First, not all patients were 
tested for tubal factors of infertility. Second, spermiogramm analysis was done only in  
partners who had been already treated within the scope of in-vitro fertilisation. 
Oligozoospermia or azoospermia were diagnosed in twelve (32.4%) partners (both 




On the other hand, we assume that the16 week period of metformin treatment was too 
short to influence the reproductive function in our patients more profoundly.   
 
The clinical pregnancy rate reported by trials comparing metformin as a single agent 
with placebo did not show evidence of benefit (Ng et al., 2001; Fleming et al., 2002). 
However, the addition of metformin to clomiphene citrate (CC), results in an improved 
ovulation and pregnancy rate in both unselected and CC-resistant PCOS patients.  In 
the trial by El-Biely and co-workers (2001), metformin in combination with CC was 
compared to CC alone in 90 women, with both ovulation and pregnancy as an end 
point. Patients in the CC plus metformin group had a higher ovulation rate (80% vs. 
65%), higher pregnancy rate per patient (29% vs. 8%), and a lower rate of ovarian 
hyperstimulation syndrome (9% vs. 69%).  
 
Taken together, our findings suggest that metformin treatment may restore menstrual 
abnormalities but  the duration of the trial and the dose of metformin were possibly 






5. SUMMARY  
 
 
5.1. English Version 
 
The present randomised,  placebo-controlled study was designed to compare the 
antihyperglycemic drug metformin vs. placebo combined with lifestyle modification in the 
treatment of polycystic ovary syndrome in obese women. Special attention was paid to 
the effects of this medication on insulin and glucose metabolism, endocrine and 
biochemical parameters, and menstrual function. 
 
Forty six  infertile women with PCOS, aged between 22-39 years and mean BMI 38.1; 
(range 28.1–49.0 kg/m²) were recruited in  the Division of Reproductive Medicine at the 
University Hospital Charité. Fifteen (32%) patients revealed regular menstrual cyclicity, 
24 (52%) patients had less than four cycles in the last six months and seven (16%) 
women had chronic amenorrhoea. The polycistic ovaries were demonstrated by 
transvaginal ultrasound in all volunteers. 
 
The trial included five monthly visits. At each visit ( at week 0, 4, 8, 12 and 16) all  
women underwent ultrasound scanning of the ovaries, recording of menstrual pattern, 
anthropometric and blood pressure measurements and recording of side-effects of 
metformin. Group therapy with aspects in nutrition and physical activity was conducted 
monthly. Each woman received individual counselling by a dietician. Therapy with 
metformin or placebo  was initiated in a randomised double-blind trial of 1.5 g daily for 
16 weeks. 
 
Changes of endocrinological and metabolic parameters such as  FSH, LH, prolactin, 
estradiol, testosterone, free testosterone, DHEA-S and SHBG, total cholesterol, 
triglycerides, HDL-cholesterol, LDL-cholesterol, insulin, glucose, HbA1c, leptin and IGF-




Blood for the endocrine investigations was obtained before the start of the metabolic 
studies.  A 75-g oral glucose dose was administered, and intravenous blood was 
obtained for glucose and insulin determination, basally, at 60 and 120 min through the 
catheter. The response of glucose and insulin to the OGGT was analysed by calculating 
the AUC (area under the curve). Statistical analysis was performed by the SPSS 
(Statistical Package for the Social Sciences),  Version 11.0. Changes during the 
treatment within groups were evaluated by means of the Wilcoxon matched-pairs test. 
 
In the present study, metformin therapy resulted in a reduction of hyperinsulinemia in 
obese women with PCOS, with a parallel increase in SHBG concentrations and a 
tendency for  improvement of high density lipoprotein status and amelioration of the 
menstrual pattern. A significant weight loss was achieved only in the metformin-treated 
group although all patients were advised to follow dietary restriction and to take regular 
exercises. 
 
However, contrary to our postulate and results reported by most other studies, we found 
no significant changes in serum total and free testosterone levels in response to 
metformin. We postulated that the major effect of metformin in obese women on 
androgen secretion is mediated by changes in hyperinsulinemia and subsequently in 
SHBG rather than by direct inhibition of ovarian androgen production. 
 
The subgroup analysis, according to the body mass index, demonstrated significant 
changes in AUC insulin levels and SHBG concentrations in obese PCOS women with 
BMI<37 after 16 weeks of metformin treatment. Patients with morbid obesity exhibited a 
significant  increase in fasting insulin levels. There was no difference in insulin 
concentrations in response to oGTT and SHBG concentrations in morbid obese women. 
This finding suggests that body weight is an important factor for clinical response to 
metformin. On the other hand, less obese women had significantly higher fasting insulin 
concentrations and in respond to oGTT insulin concentrations before the treatment. This 
could mean that metformin treatment can be more efficient in hyperinsulinemic patients 




After metformin treatment, in two of six patients with severe amenorrhea the cycle 
returned to normal, one woman became oligomenorrheic and three patients remained  
amenorrheic. These results appear to suggest that metformin administration was 




Three women got pregnant during the study; one woman in the metformin-treated group 
and two women in the placebo-treated group. This finding was unexpectedly low for us, 
taking into consideration the results of previous studies. The male infertility factor in the 
present study contributed to the low pregnancy rate. We believe that a higher dose of 
metformin and/or longer duration of administration may have a distinct effect on 
thereproductive function in very obese women with PCOS. 
 
Metformin therapy was well tolerated by the majority of patients. Three of twenty three 
(13%) patients in the metformin-treated group dropped out of the trial. Clinically,  this 
low dropout rate is important and indicates that  the usual  side effects on this dosage 
are not severe. Nevertheless, women prescribed metformin should be adequately  
counselled and actively supported during metformin treatment. 
 
In conclusion, we have demonstrated that metformin treatment has beneficial effects on 
menstrual function and metabolic factors in obese women with PCOS. This finding 
support a future therapeutic role of metformin, however, it should  be used in 
combination with general lifestyle improvements, and not as a replacement for physical 
activity and  a diet. Further well-designed, controlled trials are required to determine 
proper dosages and duration of treatment.  The primary end point of subsequent studies 
should be pregnancies and live-birth rate. 




5.2. Deutsche Version 
 
Ziel der vorliegenden randomisierten, placebo-kontrollierten Studie war es, die 
Auswirkung des antihyperglykämischen Medikaments Metformin in Kombination mit 
Ernährungsberatung und Sport auf übergewichtige Frauen mit PCOS zu ermitteln. 
Besondere Aufmerksamkeit wurde der Wirkung des Medikaments hinsichtlich Insulin 
und Glukose-Stoffwechsel, endokrinologischen und biochemischen Parametern, sowie 
dem Menstruationszyklus gewidmet. 
 
An der Studie der Abteilung für Reproduktionsmedizin der Charité, Berlin, nahmen 46 
infertile Frauen mit PCOS teil. 15 (32%) der Patientinnen wiesen einen regulären 
Menstruationszyklus auf,  24 (52%) hatten weniger als vier Zyklen in den letzten sechs 
Monaten und sieben (16%) der Frauen litten an chronischer Amenorrhoe. Die 
polyzystischen Ovarien wurden mittels transvaginalen Ultraschalls festgestellt. 
 
Die verabreichte Dosis von Metformin bzw. Plazebo betrug 1,5 g täglich über einen 
Zeitraum von 16 Wochen. Fünf monatliche Visiten wurden durchgeführt. Bei jeder Visite 
(zur ersten, vierten, achten, zwölften und vierzehnten Woche) wurden die Ovarien mit 
Ultraschall untersucht, der Menstruationszyklus festgestellt, Gewicht und Blutdruck 
gemessen sowie Nebenwirkungen überprüft. Monatlich wurde eine Ernährungsberatung 
angeboten. Jede Teilnehmerin erhielt darüber hinaus individuelle dietätische Beratung.  
 
Die Blutabnahme für die Hormonbestimmung erfolgte jeweils vor dem oralen Glucose-
Toleranz-Test. Das Blut für die Glucose- und Insulinbestimmung wurde basal, zur 60. 
und 120. Minute entnommen. Als Parameter für die Insulinsekretion wurde mit der 
Trapezmethode die „area-under-the-curve (AUC)“ für Insulin berechnet. Die statistische 
Auswertung erfolgte mit Hilfe von  SPSS (Statistical Package for the Social Sciences),  
Version 11.0. Veränderungen während der Behandlung wurden mittels des Wilcoxon-




Das zentrale Ergebnis der vorliegenden Studie ist: Die Metformin-Therapie führte zu 
einer Reduktion der Hyperinsulinämie bei übergewichtigen Frauen mit PCOS. Daneben 
wurden eine signifikante Zunahme des SHBG-Spiegels festgestellt. Ein weiterer Befund 
war eine Tendenz zur Verbesserung der HDL-Werte. Die Menstruationszyklen zeigten 
eine Tendenz zur Normalisierung. Diese Effekte traten unabhängig von einer 
Gewichtsreduktion auf. Ein deutlicher Gewichtsverlust wurde nur in der 
Metformingruppe beobachtet, obwohl allen Patientinnen Diät und Sport empfohlen 
worden waren. 
 
Entgegen unseren Erwartungen und den Ergebnissen anderer Studien wurde keine 
signifikante Veränderung beim gesamt- und freien Testosteron festgestellt. Wir 
vermuten, dass der Haupteffekt der Metformintherapie auf die androgene Sekretion bei 
adipösen Frauen durch Veränderungen der Insulinsekretion und in der Folge im SHGB-
Spiegel zu suchen sind, und nicht in der direkten Verhinderung von ovarieller 
Androgenproduktion.  
 
Nach 16wöchiger Metformintherapie zeigte die Subgruppen-Analyse mittels des BMI-
Indexes eine signifikante Veränderung der Insulinwerte im oGTT und des SHBG-
Spiegels bei PCOS-Patientinnen mit BMI<37. Adipöse Frauen mit BMI>37 wiesen eine 
deutliche Zunahme des nüchternen Insulin-Spiegels sowie keine Veränderungen der 
Insulinkonzentration im oGTT und SHBG-Spiegel auf. Dieses Ergebnis lässt vermuten, 
dass Körpergewicht ein wichtiger Faktor für klinischen Erfolg bei Metformin-Therapie 
darstellt.  Andererseits hatten weniger adipöse Patientinnen höhere nüchterne und 2-h 
Insulinwerte im oGTT-Ausgangsniveau. Dies kann bedeuten, dass Metformintherapie 
bei hyperinsulinemischen  Frauen unabhängig vom Körpergewicht effektiver sein kann.   
 
Nach 16wöchtiger Metformin-Therapie bekamen zwei von sechs Patientinnen mit 
Amenorrhoe einen regulären Zyklus, eine Frau bekam Oligomenorrhoe und drei 
Patientinnen blieben amenorrhoisch. Diese Ergebnisse deuten darauf hin, dass 
Metformin-Einnahme zu einer Verbesserung der Menstruationsfunktion bei PCOS-




Drei Frauen wurden während der Studie schwanger: eine Frau in der Metformin-
therapierten Gruppe und zwei Frauen in der Placebo-Gruppe. Dieses Ergebnis 
erscheint angesichts früherer Studien überraschend niedrig. Der männliche 
Infertilitätsfaktor in der vorliegenden Studie dürfte zu dieser niedrigen 
Schwangerschaftsrate beigetragen haben. Unsere Studienergebnisse sind 
möglicherweise auch dadurch beeinflusst, dass die Dosierung für adipöse Patientinnen 
zu niedrig war bzw. die Behandlungsdauer zu kurz war, um die Reproduktionsfunktion 
zu beeinflussen.  
 
Metformin-Therapie wurde von den meisten Patientinnen gut vertragen. Drei von 23 
Patinentinnen (13%) mussten die Studie vorzeitig abbrechen. Aus klinischer Sicht ist 
diese niedrige Abbruchrate wichtig, weil sie zeigt, dass Nebeneffekte bei dieser 
Dosierung nicht sehr stark ausgeprägt waren. Dennoch sollten Frauen, denen 
Metformin verschrieben wird, angemessen beraten und während der Therapie betreut 
werden.  
 
Zusammenfassung: Wir haben zeigen können, dass Metformin -Therapie günstige 
Auswirkungen auf den Menstruationszyklus und metabolische Faktoren bei adipösen 
Frauen mit PCOS hat. Dieses Ergebnis spricht für die Behandlung mit Metformin, die 
allerdings nicht ohne allgemeine Ernährungsumstellung und begleitende körperliche 
Aktivitäten geschehen sollte.  
 
Weitere kontrollierte Studien sind nötig, um die optimale Dosierung und Dauer der 
Behandlung mit Metformin festzulegen. Das Endziel künftiger Studien sollten 
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7. LIST OF ABBREVIATIONS  
 
ACTH  Adrenocorticotropin Hormone 
ALT Alanine Aminotransferase 
AST Aminotransferase 
AUC  Area Under The Curve 
BMI Body Mass Index 
CC  Clomiphene Citrate 
CT  Computer Tomography 
DDT  Chlorophenotanum technicum 
DHEA  Dehydroepiandrosterone 
DHEAS Dehydroepiandrosterone sulfate  
DM Diabetes mellitus 
E2  Estradiol 
EM  Endometrial Cancer 
FAI Free Androgen Index 
FFA  Free Fatty Acids  
FSH  Follicle-Stimulating Hormone 
GGT Gamma-Glutamyltransferase 
Hb1Ac Glycated Haemoglobin 
HCG Human Chorion Gonadotropin 
HDL- cholesterol High-Density Lipoprotein (HDL) cholesterol 
HOMA Homeostasis Assessment Model 
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IGF  Insulin like Growth Factor 
IGFBP Insulin like growth Factor Binding Protein 
IR Insulin Resistance 
LCOS  Laparoscopic Ovarian Drillling 
LDL-cholesterol Low-Density Lipoprotein (LDL) cholesterol 
LH  Luteinizing Hormone 
NS Not Significant 
OGTT  oral Glucose Tolerance Test 
PCO  Polycistic Ovaries 
PCOS  Polycystic Ovary Syndrome 
QUICKI Quantative  Insulin Sensitivity Check Index 
RCT  Randomized Controlled Trial 
RIA  Radio Immuno Assay 
SAT  Subcutaneous Adipose Tissue 
SD  Standard Deviation 
SHBG  Sex-Hormone Binding Protein 
SPSS   Statistical Package for the Social Sciences 
T Testosterone 
TAT Total Adipose Tissue 
TSH Thyroid Stimulating Hormone 
TT  Total Testosterone 
VAT  Visceral Adipose Tissue 
WHR  Waist-to-Hip Ratio 
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1. Jetzige oder frühere Beschwerden und Krankheiten 
 
Table 16: Symptome   
Beschwerden j n Symptome/ Beschwerden j n 
Leistungsschwäche    Unregelmäßiger Herzschlag   
Müdigkeit/ Abgeschlagenheit    Herzschmerzen unter Belastung   
Unruhe/ Nervosität   Herzschmerzen in Ruhe   
Schwitzen    Luftnot unter Belastung   
Hitzewallungen   Luftnot in Ruhe   
Kältegefühl   Nächtliches Wasserlassen/ wie oft?   
Schwindel   Wadenschmerzen unter Belastung   
Sehstörungen    Wadenschmerzen in Ruhe   
Konzentrationsschwächen    Kribbeln in Händen/ Füßen   
Vergesslichkeit   Knochen-, Gelenkschmerzen / wo?   
Schlafstörungen    Gelegentlich Durchfall   
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Einschlafen am Tage   Gelegentlich Verstopfung   
Schnarchen/ nächtliche 
Atemaussetzer 
  Heißhunger   
Nasenbluten    Libidostörungen   
Herzklopfen   andere   
 
Table 17: Krankheiten 
Krankheit ja seit wann? nein unbekannt 
Bluthochdruck     
Erhöhte Blutfette     
Gestörte Glucosetoleranz     
Herzgefäßerkrankung     
Herzinfarkt     
Herzschwäche     
Verengung andere Gefäße     
Schilddrüsenerkrankungen     
Sonstige Hormonstörungen     
Nierenerkrankungen      
Gallensteine     
Thrombose      
Andere     
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Frühere Erkrankungen/Operationen ( an Organen, Nerven, Knochen, Gelenken,  





Geburtsgewicht (wenn bekannt)..................... 
Geburtsgroße (wenn bekannt)........................ 
 
2. Familiärer Hintergrund 
  
Besteht oder bestand bei Ihren Verwandten folgende Erkrankungen oder 
Beschwerden? 
 
Table 18: Familiärer Hintergrund 
 Mutter Vater Kinder Geschwister Großeltern Onkel/Tanten 
Erkrankungen ja/nein ja/nein ja/nein ja/nein ja/nein ja/nein 
Übergewicht       
Bluthochdruck       
Schlaganfall       
Herzkranz-
gefäßerkrankung 
      
Herzinfarkt       
Nierener-
krankungen 
      
Altersdemenz       
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Zuckerkrankheit       
Gallenstein-
Operation  
      
Schilddrüsener-
krankungen 
      
Sonstige Hormon-
störungen 
      
Tumoren       
Andere       
 
3. Weitere Angabe zur Person  
 
Große Gewicht 
Übergewicht: ja/nein            wenn ja, seit wann 
 
Ursachen/Gründe Ihrer Meinung nach:  
............................................................................................................................................
............................................................................................................................................ 
Bewusste Versuche der Gewichtsabnahme: 






Abnahme/ Zunahme pro Zeitraum( in letzen Jahren): 
............................................................................................................................................ 






 Sportliche Betätigung ( was, wie viel pro Woche) 
............................................................................................................................................
............................................................................................................................................ 






Haben Sie Probleme beim Stuhlgang? ja/nein  
oder beim  Wasserlassen? ja/nein  
Nehmen oder nahmen Sie Abführmittel(Laxantien)? Ja/nein 
Nehmen oder nahmen Sie Entwässerungsmittel(Diuretika?) ja/nein  
Andere Medikamente ( möglichst alle aufzählen, von wann bis wann) 
............................................................................................................................................ 
............................................................................................................................................ 
Sind Sie gegen irgendetwas allergisch (Medikamente, Nahrungsmittel, Pollen usw.)? 
........................................................................................................................................... 
............................................................................................................................................ 





        ATTACHMENT  
  
 106
Sind Sie an ihrem Arbeits-/ ausbildungsplatz besonderen Belastungen ausgesetzt 
(künstliches Licht, Lärm, Staub, Gas , andere)?......................................................... 
 
 
4. Gynäkologische Angaben  
 
In welchem Alter trat zum ersten mal die Regelblutung auf?........................................ 
Wann war die letzte Regelblutung? ................................................................................... 
Abstand, Dauer( in Tagen) und Stärke ( 1 schwach, 2 mittel, 3 stark) der Regelblutung:. 
............../..................../..................... 
Beginn auffälliger Unregelmäßigkeiten 
............................................................................................................................................ 
Zwischenblutungen............................................................................................................. 
Dauer des Kinderwunsches................................................................................................ 
Glauben Sie, daß es bisher Unstände gab, die das Eintreten  einer Schwangerschaft 
verhinderten?...................................................................................................................... 
Arbeitsplatz/-zeiten      ....................................................................................................... 
Abwesenheit/Trennung v. Partner z. B. beruflich, räumlich................................................ 
andere................................................................................................................................. 
Wie häufig haben Sie durchschnittlich sexuellen Verkehr? 
ca............ pro Woche 
ca. .......... pro Monat 
Pille ( welche, in welchem Zeitraum) 
............................................................................................................................................ 
Andere hormonelle Medikamente 
............................................................................................................................................ 
Geburten(wann).................................................................................................................. 















Kinn   
Brust   
Bauch   
Pubes   
Arme   




Seborrhöe( ölige Beschaffenheit der Haut und Haare) ja /nein    
Akne(wo)........................................................................................................................ 
Haarausfall  ja/nein 
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Haben Sie  in den letzen Monaten oder Jahren die morgendliche Temperatur gemessen 
und/ oder Temperaturkurve geführt? ja/nein 
 
5. Ernährungsanamnese  
Wie viele Mahlzeiten nehmen Sie am Tag zu sich?.......................................................... 
Wo essen Sie?  ................................................................................................................. 
Wann nehmen Sie die Hauptmahlzeiten zu sich?(Uhrzeit) 
............................................................................................................................................ 
Was essen Sie am liebsten? 
........................................................................................................................................... 
Naschen Sie gern? Wann? 
Was?................................................................................................................................. 
Haben Sie schon Diäten ausprobiert, wenn ja welche? 
............................................................................................................................................ 
Haben Sie schon versucht, durch Erbrechen 
abzunehmen?.....................................................................................................................
. 
12.2. Patient Consent 
 
Einwilligungserklärung an der Studie  
 
Hiermit willige ich in die Teilnahme zum prospektiven randomisierten 
placebokontrollierten Parallelgruppenvergleich über 16 Wochen hinsichtlich 
Schwangerschafts- und Ovulationsraten bei übergewichtigen/adipösen Patientinnen 
(BMI ≥ 27 kg/m2) mit Polyzystischem Ovarsyndrom unter einer Therapie mit Metformin 
(500-1500 mg/d) ein. 
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Ich erkläre die Einwilligung zur Teilnahme an der Studie, meine Teilnahme ist freiwillig 
und kann jederzeit von mir ohne Nachteil für meine medizinische Behandlung 
widerrufen werden. Solange ich an  der Studie teilnehme, verpflichte ich mich, 
regelmäßig zu den Visiten und Untersuchungen zu erscheinen und die Studie regulär 
oder auf Wunsch vorzeitig mit einer Abschlussuntersuchung zu beenden. 
                                                                                         
Ort, Datum                                   Unterschrift des Patienten 
 
Erklärung des Arztes 
Ich habe den Patienten über Wesen, Bedeutung und Tragweite der Studie aufgeklärt. 
Die Patientenaufklärung wurde mit dem Patienten besprochen. Eine Kopie der 
Einwilligungserklärung wurde dem Patienten ausgehändigt. 
 
……………………………. ……………………………… 
Ort, Datum                                   Unterschrift des Arztes 
 
Vertraulichkeit der Daten 
Ich erkläre mein Einverständnis zur Überprüfung der richtigen Übertragung meiner 
Untersuchungsbefunde in anonymisierte Dokumentationsbogen und entbinde nur für 
diesen Zweck meinen behandelnden Arzt von der ärztlichen Schweigepflicht und der 
Einhaltung der Bestimmungen des Bundesdatenschutzes. 
 
…………………………………. ……………………………… 
Ort, Datum                                   Unterschrift des Patienten 
    
12.3. Patient Information 
Sehr geehrte Patientin, 
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seit langem wünschen Sie sich mit ihrem Lebenspartner ein Baby. Sie haben schon 
einige IVF-Versuche ohne Erfolg unternommen. Ihr behandelnder Gynäkologe hat ein 
Polyzystisches Ovarsyndrom (PCOS) diagnostiziert.  
Etwa fünf bis sieben Prozent der Frauen leiden unter diesem Syndrom, oftmals ohne es 
zu wissen: In ihren Eierstöcken (Ovarien) haben sich Zysten (mit Flüssigkeit gefüllte 
Bläschen) gebildet und häufig reift kein befruchtungsfähiges Ei heran, denn die 
Produktion der weiblichen Geschlechtshormone (Östrogene) in den Ovarien ist gestört. 
Es handelt sich hierbei um eine Störung, die sowohl die Funktion der Eierstöcke als 
auch die der Schleimhaut der Gebärmutter beeinträchtigt. Gleichzeitig kommt es wegen 
des Mangels an Östrogenen zu einem relativen Überschuß der männlichen 
(androgenen) Geschlechtshormone. 
Durch Veränderungen im Hormonhaushalt kommt es zu Regelblutungsstörungen 
(Amenorrhoe = keine Regelblutung; Oligomenorrhoe = unregelmäßige Regelblutung), 
Veränderung der Behaarung mit typischem männlichen Erscheinungsbild (Bartwuchs, 
Haarausfall am Stirnansatz, Behaarung in der Mittellinie des Unterbauches), Neigung 
zur Akne.  
Weniger bekannt sind die Zusammenhänge dieser Hormonstörungen mit dem Zucker- 
und Fettstoffwechsel. Patientinnen mit einem PCOS sind häufiger als gleichaltrige 
Frauen ohne diese Störung übergewichtig. Damit verbunden besteht eine relative 
Unempfindlichkeit der Muskulatur für Insulin (Hormon, welches die Bauchspeicheldrüse 
nach der Resorption von Zucker, entstanden durch den Abbau der Kohlenhydrate im 
Darm, in das Blut ausschüttet). Der Zucker wird normalerweise durch Insulin in die 
Muskelzellen eingeschleust. Durch die relative Unempfindlichkeit der Muskulatur für 
Insulin wird Zucker bevorzugt in die Fettzelle und die Leber gebracht. Dadurch entsteht 
die Neigung zum Übergewicht und zur Produktion von Fett aus Zucker.  
Reaktiv schüttet die Bauchspeicheldrüse nach Nahrungszufuhr mehr Insulin aus, um 
das Problem der schlechten Nährstoffversorgung der Muskulatur zu lösen. Sie können 
sich vorstellen, dass Bewegungsmangel und ungünstige Ernährung diese Situation 
stark verschlechtern kann. Nach vielen Jahren des Bestehens einer derartigen Störung 
sind die Blutfettwerte erhöht bzw. kann eine Diabetes mellitus (Zuckerkrankheit) 
resultieren. Der permanent in diesem Kreislauf steigende Insulinspiegel stört die 
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normale Produktion von weiblichen Geschlechtshormonen und verstärkt damit das 
PCOS.  
Aus diesem Grund ist es für eine erfolgreiche Therapie zur Behandlung Ihres unerfüllten 
Kinderwunsches  unbedingt notwendig, diesen Kreislauf zu durchbrechen. Dann 
nämlich normalisieren sich die Hormonspiegel von Östrogenen, Androgenen und Insulin 
und Sie haben gute Chancen, schwanger zu werden.  
In Zusammenarbeit mit der Poliklinik der Charité bieten  wir Ihnen  eine kombinierte 
Behandlung zur Gewichtsreduktion und zur Verbesserung der hormonellen 
Stoffwechsellage an. Ziel der Behandlung, die im Rahmen einer klinischen Studie mit 
insgesamt sechzig Frauen durchgeführt wird, ist die Normalisierung der Monatszyklen 
bzw. der Eintritt einer Schwangerschaft. 
 
Hierfür kommen folgende Therapieansätze in Frage: 
Medikamentöse Therapie mit Metformin: 
 
Metformin wird bei der Behandlung von Diabetes mellitus Typ II b (infolge von Versagen 
der Kreislaufes: Insulinunempfindlichkeit am Muskel → erhöhte Insulinausschüttung → 
absinkender Blutzuckerspiegel → Heißhunger → erhöhte Nahrungszufuhr kombiniert 
mit Bewegungsmangel, dann absinkender Insulinspiegel mit Erhöhung des 
Zuckerspiegels) eingesetzt.  
Metformin steigert die Aufnahme von Zucker in die Körperzellen, insbesondere in die 
Leberzellen. Gleichzeitig wird die Neubildung von Zucker in der Leber gebremst. 
Dadurch wird der Zuckerstoffwechsel günstig beeinflusst und die Bauchspeicheldrüse 
schüttet weniger Insulin aus.  
In zahlreichen internationalen Studien konnte gezeigt werden, dass durch die sinkenden 
Insulinspiegel die männlichen Hormone vermindert und der Menstruationszyklus 
normalisiert werden konnte. Es ist zu vermuten, dass sich unter einer Therapie mit 
Metformin die Vorraussetzungen für die Produktion von Eizellen und auch für die 
Einnistung eines befruchteten Eis günstiger sind. 
        ATTACHMENT  
  
 112
Jede medikamentöse Therapie hat Nebenwirkungen, bei einer Therapie mit Metformin 
sind diese selten: z.B. Durchfälle, vereinzelt Kopfschmerzen. 
 
Steigerung der körperlichen Betätigung/Umstellung der Ernährung:   
 
Durch Steigerung der körperlichen Betätigung insbesondere durch eine Training, 
welches jeweils zur Hälfte aus Herz-Kreislauf- und Widerstandstraining besteht sowie 
durch Reduktion der Fettzufuhr, der Saccharose, Glucose und Fructosezufuhr (Einfach- 
und Zweifachzucker) wird der Zucker-, Fett- und Insulinstoffwechsel positiv beeinflusst.  
Einzelne Fälle aus unserer Sprechstunde lassen vermuten, dass damit die 
Vorraussetzungen für die Produktion von Eizellen und auch für die Einnistung eines 
befruchteten Eis günstiger sind. 
 













Die Behandlung läuft über  4 Monate. 
Die Wahl der Therapie erfolgt per Zufallsgenerator. 
Bei Teilnahme erklären sie sich mit jedem der aufgeführten Therapieverfahren 
einverstanden. 
Die Untersuchungen und Therapien können sie dem beigefügten Visitenplan 
entnehmen und mit ihrem Arzt besprechen. 
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Im Lauf der Studie wird bei Ihnen ein Oraler Glukosetoleranz-Test (zur Bestimmung der 
Glukosestoffwechselstörungen ) durchgeführt.  
Sie müssen sich auf diesen Test vorbereiten, d.h.: 
mindestens 3 Tage lang übliche Essengewohnheiten. 
Mindestens 3 Tage lang Absetzen störender Medikamente( Z.B.: Anthihyperhtensiva, 
Laxantien, Salycylate, Transquilizer, Corticosteroide), sofern dies ohne Gefahr möglich 
ist.   
Fortsetzung der normalen körperlichen Tätigkeit, Bettlägerigkeit oder übermäßige 
körperliche Aktivitäten sind auszuschließen.   
24 Stunden vorher keinen Alkohol. 
12 Stunden vor dem Test nüchtern (d.h., wenn Sie zuletzt am Vorabend etwas 
gegessen haben, am Morgen des Untersuchungstermins bitte kein Frühstück zu sich 
nehmen).  
 
Durchführung des Tests: 
Nach venöser Blutentnahme zur Bestimmung der Nüchternglucose und des 
Nüchterninsulins erfolgt die Verabreichung von 75 g Glucose in ca. 200 ml ungesüßter 
Flüssigkeit (warmer Tee). Nach 30, 60, 90 und 120 min werden weitere venöse 
Blutentnahmen zur Bestimmung von Glucose und Insulin vorgenommen. 
 
Bio-Impedanz-Analyse ( BIA): Die Untersuchung zur Körperzusammensetzung wird mit 
einem Gerät zur Impedanzanalyse bei verschiedenen Frequenzen  tetrapolar 
durchgeführt. Es dient so der Ermittlung des Gesamtkörperwassers (TBW), der 
Fettmasse (FM), der Magermasse (LBM), der zellulären und extrazellulären 
Körperbestandteile (BCM,ECM).  
 
Die weiteren Untersuchungen, die nötig sind, führt der folgende Visitenplan auf.  
Dieser Plan zeigt Ihnen, wann welche Untersuchungen geplant sind. 
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Liebe Patientinnen,  
 
wir freuen uns, dass Sie sich zur Teilnahme an der Studie entschlossen haben. Wir 
hoffen, dass Sie Ihnen Erfolg bringen wird und wünschen Ihnen Alles Gute. 
 
Wenn Sie Fragen haben, stehen wir Ihnen jederzeit zur Verfügung. Sie erreichen uns 
telefonisch unter der Nummer 030- 450-56-4287. 
Unser Team besteht aus:  
OÄ  Dr. med. B. Pfüller  -  Leiterin der Abteilung für Reproduktionsmedizin 
Dr. med. A. Machlitt 
Dr. med. A. Sarut – Lopez 
Dr. med. S.Klaua - Sprechstunde für Adipositas: Tel: 030- 450- 514053 
Krankenschwestern  Gerlinde,  Doris, Sybille, Angela 
Unsere Adresse ist : Luisenstraße 11-13,  Poliklinik der Charité, Berlin-Mitte 
 
Table 19: Visitenplan (Übersicht)  
Rd.-Nr. Name, Vorname, Geburtsdatum 
Anschrift 
Tel.-Nr.: 





Visite 0 Visite 1 Visite 2 Visite 3 Visite 4 Visite 5 
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Demogr. Daten X      









 X X X X X 












X X X X X X 
Sonogr. 
Kontrolle 
X X X X X X 
Routinelabor 




X     X 











HbA1c, oGTT + 
Insulin). 
 X  X  X 
BIA  X  X  X 
Ernährungsanal
yse 
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